Lists of funding opportunities are updated weekly. New funding opportunities for scientists are distributed in the VPRI Update newsletter.
To submit funding opportunities, and/or be added to the VPRI Update mailing list, please send your request to VPRI@unityhealth.to
Opportunities are categorized by Sponsor Type (Tri-Agency, Other Canadian, International & NIH). Filter opportunities by keyword (e.g. Sponsor Type, CIHR, user-supplied keyword, etc.) using the Search box at right.
| Sponsor Type | Funding Program Title | Amount and Duration | Description | Deadline | |
|---|---|---|---|---|---|
| Tri-Agency | Unity Health Call for Tier 1 CIHR Canada Research Chair | -- | Unity Health is announcing an internal call for TWO Tier 1 CIHR Canada Research Chair positions to support a CIHR eligible research program that aligns with one or more of our four established pillars of world-class research and innovation. One chair will ideally fall within the scope of the Keenan Research Centre for Biomedical Science (KRCBS) and the other within the Li Ka Shing Knowledge Institute (LKSKI). In order to meet specific diversity targets mandated by the CRC program, this particular call is only open to individuals who self-identify as women or gender minorities. | April 3, 2023. | |
| Tri-Agency | CIHR and SSHRC Undergraduate Student Research Awards for Black Students | ,500 (,000 provided by funding agency, ,500 provided by faculty member’s research grant). | The Canadian Institutes of Health Research (CIHR) and the Social Sciences and Humanities Research Council (SSHRC) have introduced the USRA for Black students, modelled on NSERC’s USRA program. Successful students will work for 16 weeks over the summer on a research project under the supervision of a faculty member. At present time, these awards are exclusively open to Black student researchers. Both the student and the Faculty Supervisor must complete an application on NSERC’s portal: Completing a USRA Application. Instructions on completing the application are available here : Instructions for USRA applications. For more information, please contact: keti.dzamova@utoronto.ca | Internal Deadline: April 4, 2023 Sponsor Deadline: May 1, 2023 | |
| Tri-Agency | CIHR Other: IYS-Net Phase 1: Building Learning Health System Networks | Stream 1 Network Grants: Up to 1,000 per year for up to 5 years. | The goal of IYS-Net is to create a pan-Canadian network of Learning Health System (LHS) networks (a 'network of networks'). Through these LHSs, IYS-Net aims to improve equitable and inclusive access to evidence-informed services for mental health and substance use health and improve equitable outcomes for all youth. IYS Networks are expected to enable LHSs through various processes: (i) collecting and synthesizing data from real-world practice ('practice to data'), (ii) using that data to answer questions and generate new and useful knowledge ('data to knowledge'), and (iii) applying that knowledge to improve care to equitably meet the needs of youth, caregivers/families and communities served ('knowledge to practice'), which includes knowledge mobilization and implementation science | Registration: April 4, 2023. Application: May 17, 2023. | |
| Tri-Agency | NSERC Undergraduate Student Research Awards for Black Students and Indigenous Students | ,000 from NSERC with mandatory match from the U of T (usually from the faculty supervisor’s other research funds) of a minimum of ,500. | The Natural Sciences and Engineering and Research Council (NSERC) is providing increased opportunities for Black undergraduate students to apply for Undergraduate Student Research Awards (USRAs) that cover 16 full consecutive weeks in the summer term (between May 1st and September 1st). Students must advise the undergraduate coordinator in their department of their intention to apply for either the NSERC Black Students USRA program or the NSERC Indigenous Student USRA program. Instructions on completing the application are available here: Instructions for USRA applications. For more information, please contact: For CIHR Black Student USRA’s: Rochelle Carvalho (rochelle.carvalho@utoronto.ca); For SSHRC Black Student USRAs: Shoba Subramaniam (shoba.subramaniam@utoronto.ca). | Internal Deadline: April 19, 2023 Sponsor Deadline: April 19, 2023 | |
| Tri-Agency | SickKids Foundation-CIHR Operating Grant: New Investigator Grants in Child and Youth Health (2023) | Up to 0,000 per year for up to 3 years. | This supports new investigators for research in biomedical, clinical, health systems and services, population and public health sectors that has the potential for significant impact on children's health outcomes. As of the application deadline, the applicant: • As a principal investigator has not been awarded combined Operating Grant funding of 0,000 or more Canadian dollars. • Is within five years of their first academic appointment. Time taken for breaks in research career, including COVID-caused delays, will be considered in determining eligibility as a new investigator. • Has at least 50% of protected research time for the duration of the project. Visit the New Investigator Research Grants funding opportunity on the SickKids Foundation website for further details | April 20, 2023. | |
| Tri-Agency | CIHR Catalyst Grant: HIV/AIDS and STBBI Community-Based Research | Up to 0,000 per year for up to 1 year. | The aim of this funding opportunity is to provide seed money to support HIV and/or other STBBI CBR planning and development activities and/or research activities which represent a first step towards the pursuit of more comprehensive funding opportunities (e.g., operating grants). | May 2, 2023. | |
| Tri-Agency | CIHR Chair: Applied Public Health | The maximum amount per Chair award is up to ,150,000. | The purpose of this funding opportunity is to fund diverse mid-career applied public health researchers in Canada who will undertake inclusive and equitable applied research programs that tackle pressing public health challenges and who will work with decision makers from various sectors and communities to help support evidence-informed decisions that improve health and health equity. | Letter of Intent: May 2, 2023. Full Application (by invitation): October 4, 2023 If you wish to apply, please let us know by email to VPRI@unityhealth.to. | |
| Tri-Agency | CIHR Operating Grant: HIV/AIDS and STBBI Community-Based Research | Up to 0,000 per year for up to 3 years. | This is to contribute to the creation, dissemination and use of health-related knowledge, and to help develop research capacity, by supporting original, high-quality projects proposed and conducted in active partnership between the community and academia. It supports the partnered work of Community Leaders and Researchers in knowledge development and capacity-building initiatives of relevance to communities engaged in the fight against HIV/AIDS and/or other STBBI. | May 2, 2023. | |
| Tri-Agency | CIHR Other: CIHR Research Excellence, Diversity, and Independence (REDI) Early Career Transition Award | Mentored Phase 1: ,000/year research allowance, a ,000/year stipend for 2-3 years; Independent Phase 2: At least 0,000/year in research allowance and salary support for 3-4 years. | This will facilitate the transition of promising researchers who self-identify as Black (any gender) or racialized women into independent research faculty positions in Canadian academic, health system and research institutions. Applicants must be a trainee by the funding start date. The Primary Mentor must be an independent researcher with an academic appointment and be either the applicant's current supervisor or a principal investigator who will function as the applicant's Primary Mentor for their Phase 1 REDI project. | May 5, 2023. | |
| Tri-Agency | National Centre for Truth and Reconciliation (NCTR) and SSHRC: Reconciliation Network in Response to Call to Action 65 | Up to 0,000 per year for 5 years. | This supports establishment of a national research program with multiyear funding to advance collective understanding of reconciliation. SSHRC and the NCTR invite teams led by First Nations, Métis Nation or Inuit researchers to submit proposals for new or existing formal partnerships that contribute to our collective understanding of truth and reconciliation. Proposals could, for example, address residential schools’ history, or the ongoing legacy of residential schools and Canada’s policies of assimilation in one or more areas, including child welfare, education, language and culture, health, and justice. | May 15, 2023. | |
| Tri-Agency | CIHR Operating Grant: STBBI Research in Canada: Beyond HIV/AIDS and Hepatitis C | Up to 0,000 per year for up to 3 years. | This funding opportunity will support projects across all pillars of research (biomedical research; clinical research; health services research; and social, cultural, environmental, and population health research) with a primary focus on STBBI of public health relevance including, but not limited to: Chlamydia; Gonorrhea; Syphilis; Hepatitis B; Human papillomavirus (HPV). | May 16, 2023. | |
| Tri-Agency | CIHR Catalyst Grant: STBBI Research in Canada: Beyond HIV/AIDS and Hepatitis C | Up to 0,000 per year for up to 1 year. | The overall goal of the Catalyst Grant is to strengthen the current landscape of STBBI research in Canada, and to build capacity and spur innovation in this field, with a specific focus on STBBI of public health relevance beyond the fields of HIV and hepatitis C and in alignment with the CIHR HIV/AIDS and STBBI Strategic Plan 2022-2027. Research projects focusing primarily on HIV or hepatitis C will not be eligible for funding. | May 16,2023 | |
| Tri-Agency | CIHR Team Grant: THINC Knowledge Mobilization & Impact Hub | Up to 0,000 per year for the first year and 0,000 per year for years two (2) through and including six (6) for a total of ,200,000 per grant. | The Transforming Health with Integrated Care (THINC) Knowledge Mobilization & Impact Hub will build and support a vibrant pan-Canadian learning community involving all THINC grantees and knowledge user communities towards advancing evidence-informed integrated care transformation and catalyze progress towards achieving the Quadruple Aim and health equity (sometimes referred to as the Quintuple Aim). | May 16, 2023. | |
| Tri-Agency | CIHR New Investigator Salary Award: Health System Impact Embedded Early Career Researcher Award | 0,000 per year for 4 years. Unity Health will provide 1:1 matching for successful candidates, as ,000 in salary support and ,000 as a post-doctoral fellowship. | The NPA must be an ECR who is an independent researcher by the application deadline, and the NPA must secure a position as an embedded scientist or equivalent role at a health system organization in Canada. Universities and university-based research institutes are not eligible host health system partner organizations in this funding opportunity. | Unity Health Deadline: Please let us know if you plan to apply by email to VPRI@unityhealth.to by April 3, 2023. Internal deadlines will be provided. Sponsor Deadline: May 17, 2023. | |
| Tri-Agency | CIHR Operating Grant: BHCIA (Brain Health and Reduction of Risk for Age-related Cognitive Impairment): Knowledge Synthesis and Mobilization Grants | Up to 0,000 per year for 1 year. | This will support the development of knowledge syntheses, using an equity, diversity and inclusion lens, to assess the current state of knowledge and evidence base, and identify strengths and gaps in research areas related to the promotion of brain health and risk reduction for age-related cognitive impairment. This will include a specific focus on knowledge mobilization practices throughout the research process to increase the usefulness and uptake of findings to relevant stakeholders, including partners and knowledge users, as well as the creation of culturally appropriate, equitable and inclusive targeted knowledge mobilization products. | Registration: May 25, 2023 Application: June 22, 2023 | |
| Tri-Agency | CIHR Operating Grant : Mechanisms in Brain Aging and Dementia | Up to 0,000 per year for 3 years. | This is to advance the understanding about risk reduction and protective factors involved in promoting cognitive health and mitigating the changes that occur in the onset and progression of cognitive impairment and dementia in aging, while considering the intersection of different factors, including the social determinants of health and other structural and systemic barriers. | Registration: June 13, 2023 Application: July 12, 2023 | |
| Tri-Agency | CIHR Catalyst Grant: NWHRI: Innovation Fund - Biomedical Discovery Grants | Up to 0,000 for up to 1 year. | This is to support high risk, high reward research in high-priority areas of women's health research. This funding opportunity will support basic science and/or other types of preclinical studies that have the potential to make significant advancements in women's health. Projects are expected to involve cells, tissues, body parts, and/or biomarkers. Studies focused on female technology (Femtech) are also eligible. | Registration: June 21, 2023. Application: July 19, 2023. | |
| Tri-Agency | CIHR Pre-Announcement: National Women's Health Research Initiative: Pan-Canadian Women's Health Coalition | It is anticipated that .6M will be allocated to the National Women's Health Research Initiative: Pan-Canadian Women's Health Coalition. | The Coalition will be composed of virtual hubs across Canada linked through a coordinating centre. The hubs and the coordinating centre will work together collectively to maximize the visibility and impact of women's health research and practice in Canada by committing to the principles of equity, diversity, inclusion, and Indigenous Rights. Applications for the hubs and coordinating centre will occur through two separate funding opportunities. | Anticipated Launch: Fall 2023. | |
| Tri-Agency | NSERC Alliance Grants | ,000 to million per year for 1-5 years | Support university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors. NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office. | No Deadline | |
| Tri-Agency | NSERC Alliance International | Catalyst Grants: ,000 for 1 year. Collaboration Grants: Up to 0,000 per year for up to 3 years. | These are for Canadian university researchers working in the natural sciences and engineering in partnership with international collaborators from the academic sector. The overall objectives are to: 1) allow Canadian researchers to initiate the development of international collaborations; and 2) provide support for Canadian researchers participating in international collaborative projects of global importance and benefit to Canada. The applicant and any Canadian co-applicants must have an active NSERC peer-reviewed grant, as primary applicant, at the time of application. NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office. | No Deadline | |
| Other Canadian | Alberta Gambling Research Institute (AGRI): Various Opportunities | Leveraging Grants: Up to ,000. Team Development Grants: Up to ,000 for up to 18 months. Small Grants: T Up to ,000 for up to 1 year. | Leveraging Grants: To enable researchers, with non-AGRI funding to augment projects with a gambling-related component. Value: Up to ,000. Deadline: Rolling call. Team Development Grants: To support the development of multi/interdisciplinary teams of academic researchers, among Partner Universities, nationally, internationally, and other stakeholders in order to establish research programs Value: Up to ,000 for up to 18 months. Deadline: Rolling call. Small Grants: To support small developmental initiatives typically intended to lead to major grant applications. Value: Up to ,000 for up to 1 year. Deadlines: October 1st and May 1st each year. NOTE: For AGRI grants, the applicant must be one of the principal investigators and have grant-holding status at the University of Alberta, Calgary, or Lethbridge. Research collaborators may come from other institutions. | Leveraging Grants: Rolling call. Team Development Grants: Rolling call. Small Grants: October 1st and May 1st each year. | |
| Other Canadian | Pre-Announcement: Canadian Cancer Society (CCS) Emerging Scholar Research Grants | Value: Up to 0,000 per year for up to 5 years. | These aim to support the establishment of promising early career investigators from across Canada. The Research Grants will advance cancer research spanning all pillars of research (biomedical; clinical; health services; and social, cultural, environmental & population health). | TBA when call launched in February/March 2023. | |
| Other Canadian | TRANSFORM HF 2023 Collaboration Starter Grant | Up to ,000 for 1 year | These are offered to encourage, foster, and support members of the TRANSFORM HF community working collaboratively on research and project proposals that advance our mission and expand our network. Three types of supports are available: • For proposal development meetings, collaborative project activities, patient or Knowledge Keeper compensation and facilitation; • For scoping and preliminary project research and data collection; • For research proposal writing and editing. | March 24, 2023. | |
| Other Canadian | Data Sciences Institute (DSI): Various Opportunities | href=https://datasciences.utoronto.ca/critical-investigation-of-data-science-grant/>Critical Investigation of Data Science Grant :This provides seed funding for scholars to engage in critical investigations of data science. Projects can vary in scope from analysis of specific data science projects and approaches to the articulation of potential harms in data science writ large. A variety of methodological and epistemological approaches are welcome, including critical analysis, social inquiry, phenomenology, qualitative investigations of lived experiences, content analysis, rhetorical approaches, and/or the creation or evaluation of models, algorithms, and other data science methodologies. Value: ,000 for up to 12 months. href=https://datasciences.utoronto.ca/computational-and-quantitative-social-sciences-grant/>Computational & Quantitative Social Sciences Grant: Value: ,000 for up to 12 months. | Deadlines: March 24, 2023. | ||
| Other Canadian | Angels Den 2023 Call for Proposals | 0,000 | The St. Michael’s Foundation is pleased to announce the call for proposals for Angels Den 2023. Since 2015, St. Michael’s Foundation has worked closely with the hospital’s research leadership to grow the Angels Den into Canada’s biggest medical research competition. Here is a quick overview of this incredible event, or check out the full show at AngelsDen.ca This year, we plan to award 0,000 in funding to support ground-breaking research. For a copy of the call for proposal or the application please email VPRI@unityhealth.to | March 31, 2023. | |
| Other Canadian | Emerging and Pandemic Infection Consortium-Inspire Summer Studentships | 7,500 | These awards aim to support Black and Indigenous students who are interested in infectious diseases and to create a more diverse talent pool for the next generation of infectious disease research leaders. Faculty members who supervise an EPIC Inspire Summer Student Fellow must also commit to supporting the student in continuing their work as a fourth-year thesis project, should the student choose to do so. To apply and view the conditions of this application please visit EPIC’s website. | March 31, 2023 | |
| Other Canadian | Ontario Ministry of Transportation: Road Safety Research Partnership Program (RSRPP) 2023-24 | Value: ,0000 per year | The primary purpose of the program is to encourage policy- and program-relevant applied research on road user behavior and human factors surrounding road user safety. The secondary purpose is to facilitate the transfer of knowledge, skills, and methodologies from another discipline to road user safety research, and to foster collaborative working relationships between MTO and researchers in the academic and broader public sector community. | Sponsor Deadline: March 31, 2023 | |
| Other Canadian | Cystic Fibrosis Canada (CFC): Various Opportunities | Seed Grants: Up to ,000 for 1 year. | Seed Grants: Small, short-term grants focused on a new idea without other funding and without preliminary data. Not to be used to support an existing project that was not successful through the Basic and Clinical Research Grants competition. | Seed Grants: Anticipated April 1, 2023. | |
| Other Canadian | University of Toronto (U of T) Excellence Awards (UTEA) | Minimum of ,500; ,250 provided by U of T and must be matched by a minimum of ,250 from the student’s supervisor or the academic unit. | These provide opportunities for research experience at the undergraduate level in the natural sciences and engineering (NSE), social sciences and humanities (SSH), and introducing this year, health and life sciences (HLS). The award period is 14 full weeks during the summer term, beginning no earlier than May 1, 2023, and ending no later than September 30, 2023. | April 3, 2023. | |
| Other Canadian | Canadian Donation and Transplantation Research Program (CDTRP) 2023 Research Innovation Grant Competition | ,000 for 18 months. | The CDTRP supports research and innovation that addresses barriers within the fields of donation and transplantation, with the ultimate goal of advancing long-term health outcomes and quality of life for Canadian transplant patients.This collaborative effort between the CDTRP and its partners is intended to seed new and innovative pilot projects in the transplant and donation field. | April 12, 2023. | |
| Other Canadian | U of T Institute for Pandemics (IfP)-Emerging & Pandemic Infections Consortium (EPIC): Catalyst Grants | Up to $25,000 for 1 year. | IfP seeks proposals that address the three research themes: pandemic readiness, resilience, and recovery. Proposed projects can be specific to a single research theme or cross-cutting multiple themes. Principal applicant must be tenure-stream faculty and eligible to hold research funding at U of T or hold a primary appointment at one of the five partner hospitals of EPIC (Unity Health is a partner). At least one investigator (PI or Co-I) needs to be a member of EPIC. | April 30, 2023. | |
| Other Canadian | Dorothy Killam Research Fellowships | Value: ,000 per year for a total of up to 0,000 for 2 years | To support scholars of exceptional ability by granting them time to pursue research projects of broad significance and widespread interest within the disciplines of the humanities, social sciences, natural sciences, health sciences, engineering or studies linking any of these disciplines. To be eligible, applicants must be working at a Canadian institution(s) in the early-to-mid stage in their career (no more than 15 years since the completion of a PhD). Between 5-8 Fellowships are awarded annually. For application details, click href=https://programmekillamprogram.powerappsportals.com/en-CA/fundingopportunities/fodetails/?foid=4b490485-049f-ec11-b400-002248d5186d >here. | Deadline: June 16, 2023 | |
| Other Canadian | Toronto Dementia Research Alliance (TRDA) 2023-24 Scholarship for Graduate Dementia Research by Indigenous Students | Masters ($10K/year for 2 years; $20K total); PhD ($15K/year for 2 years; $30K total). | This is created to respond to the historical underrepresentation of Indigenous peoples in the sciences and research. Open to Masters and PhD students, who are living in or planning to move and study in Canada, and who identify as Indigenous (First Nations, Métis, or Inuit). Indigenous students should have a connection to, and have lived experience in an Indigenous community, an in-depth knowledge of culture and heritage, or past work with an Indigenous organization. | June 30, 2023. | |
| Other Canadian | Canadian Allergy, Asthma, and Immunology Foundation (CAAIF)-Miravo Healthcare Research Grant in Upper Airway Allergic Disease | 50,000 | To fund a research project focused on the area of upper airway allergic disease (including but not limited to its development, persistence, desensitization, remission, diagnosis, clinical manifestation). | May 1, 2023. | |
| Other Canadian | Brain Aneurysm Foundation Research Grant | Value: USD ,000 to ,000 each. | This supports basic scientific research directed at early detection, improved treatment modalities, and technological advances that will ultimately improve outcomes for patients with brain aneurysms, as well as projects that are translational, clinical/outcome, early detection, imaging, and SAH/SAH complications focused. This year they are also considering AI focused projects. Any project with the potential to advance basic scientific, translational, and clinical brain aneurysm research will be considered. | May 5, 2023. | |
| Other Canadian | Canadian Foundation for Pharmacy (CFP) Innovation Fund Grant | Not specified. Up to 0,000 will be available. | This supports a pharmacist engaged in research or an innovative model of pharmacy practice that seeks to advance the profession in ways that can demonstrably improve the health of patients. | Letter of Intent: May 8, 2023. Application (by invitation): TBA. Expected at end of July, 2023. | |
| Other Canadian | Cystic Fibrosis Foundation (CFF): Various Opportunities | · Clinical Pilot and Feasibility Award: Enables investigators to collect sufficient preliminary data to determine the best strategies and methods for approaching a major question that ultimately will require assessment through a larger scale research and/or multi-center, collaborative clinical trial. Value: Up to USD ,000 per year for single-centre studies or up to USD 0,000 per year for multi-centre studies. Duration of up to 2 years. Deadlines: Pre-Registration: March 8, 2023; Letter of Intent: March 22, 2023; Full Application (by invitation): August 8, 2023. • Clinical Research Award: Supports investigator-initiated clinical research projects that have the potential to make an important contribution to the Cystic Fibrosis Foundation's mission. Research projects may address diagnosis, treatment, management of disease or symptom, or the pathophysiology of cystic fibrosis, using clinical, (observational/interventional), translational, or epidemiologic study approaches. Value: Between USD 0,000-0,000 per year for up to 3 years. Deadlines: Pre-Registration: March 8, 2023; Letter of Intent: March 22, 2023; Full Application (by invitation): August 8, 2023. • Multiple Principal Investigator Clinical Award: Support or multi-investigator-initiated clinical research projects that have the potential to make an important contribution to the Cystic Fibrosis Foundation’s mission. Value: Up to USD 0,000 per year for up to 3 years. The lead institution may request up to USD ,000 in additional direct costs per year to support an administrative core. Deadlines: Pre-Registration: March 8, 2023; Letter of Intent: March 22, 2023; Full Application (by invitation): August 8, 2023. • Health Equity Team Science Award: Support for multi-investigator research projects that have the potential to make an important contribution to health equity in the cystic fibrosis population. Value: Up to USD 0,000 per year for up to 4 years. The lead institution may request up to USD ,000 in additional direct costs per year to support an administrative core. Deadlines: Pre-Registration: March 15, 2023; Full Application: March 29, 2023. • Idea Development Award: Supports projects that will improve our understanding of the biological basis for the development and progression of cystic fibrosis-related diabetes as well as to identify potential novel therapeutic strategies to manage and treat the disease. Value: Up to USD 0,000 per year for up to 3 years. Deadlines: TBA in August, 2023. • Biological Basis for Cystic Fibrosis-Related Diabetes Program: Supports work that leads to sufficient project development to enable an application for future research funding from the Cystic Fibrosis Foundation or the National Institutes of Health. Value: Up to USD ,000 for 1 year. Deadlines: TBA in August, 2023 • CFF/NIH R01-Unfunded Award: This provides bridge funding for CF-relevant R01/R21 (or equivalent) applications that were submitted to NIH (or other governmental agencies) that scored in the 40th percentile but were not awarded by the funding agency. Value: Up to USD 5,000 per year for up to 2 years or until NIH funding is secured. Deadline: Rolling. | Various deadlines based on funding opportunity | ||
| Other Canadian | Sigma Theta Tau International Honor Society of Nursing (STTI) / Canadian Nurses Foundation (CNF) Grant | Up to USD ,000. | This supports research that advances the practice of nursing with an emphasis on nursing care issues. Nursing care research or clinical nursing research is defined as research that is practice-based or that will provide the groundwork for future practice-based research studies. Research funded through this grant must provide evidence that there is a potential impact on nursing practice, whether direct or indirect. | December 1, 2023. | |
| Other Canadian | Weston Brain Institute: Brain Health: Sleep 2023 Program | Up to $1,200,000 over 3 years. | This seeks to accelerate the research and development of sleep-based strategies that improve brain-related outcome measures relevant to (or associated with) neurodegenerative diseases of aging. This includes observational studies (e.g., studies mining existing databases, cohort studies, biomarkers studies) and interventional studies in humans (e.g., pilot studies, proof-of-concept trials, ancillary trials). Work involving animal models/data are not in scope of the program. | Letter of Intent: July 11, 2023. Proposal (by invitation): December 12, 2023. | |
| Other Canadian | U of T Emerging & Pandemic Infections Consortium (EPIC): Various Opportunities | Various values based on funding opportunity | These support multidisciplinary, collaborative and leading-edge infectious disease research. • Proof-of-Principle Grants: Support early stage and pilot level projects that show promise in developing novel understanding or innovations in the area of infectious disease and/or pandemic preparedness. Value: ,000 for 1 year. Deadline: April 14, 2023. • New Connections Grants: Support innovative projects that are fostered through cross-disciplinary collaboration across at least two research groups. Successful proposals will feature joint lead investigators from different university divisions and/or departments and/or EPIC partner institutions coming together for their first significant research collaboration. Value: 0,000 over 2 years. Deadline: April 28, 2023. • Convergence Postdoctoral Fellowships: Support postdoctoral trainees who are driving innovative infectious disease-focused projects that bridge two research disciplines. These senior trainees are expected to engage faculty from at least two different departments and/or divisions, with formal co-supervision by each. Value: 0,000 over 2 years. Deadline: April 14, 2023. • Career Transition Awards: Support postdoctoral trainees and research associates who are ready to lead an independent project. Value: 0,000 over 2 years. Deadline: April 28, 2023. • Researcher Mobility Awards: Support high-calibre doctoral students or postdoctoral fellows developing new skillsets and strengthening global linkages by providing financial support for them to undertake research training or complete collaborative field work outside of Toronto. Value: ,000 for training or field work undertaken at North American host institutions/sites; ,000 for training for field work undertaken at research institutions/sites in other countries. Deadline: May 19, 2023. | Various deadlines based on funding opportunity | |
| Other Canadian | Grand Challenges Canada: Transition To Scale (TTS) Request for Proposals | Range from 0,000 to M for 6 months up to 2 years | This seeks to support the transition to scale and sustainability of Bold Ideas with Big Impact in Global Health. It supports promising innovations with a proven impact that have the potential to save or improve lives. Applications are invited in the following areas: Maternal and Newborn Health, Digital Health, Medical Products and Technology, Community Health Worker Models, Urban Sanitation & Hygiene, and Options. Applicants must be either a non-profit organization, for-profit company, research/academic institution, or another recognized institution that is incorporated in a low- or middle- income country, with a current priority in Sub-Saharan Africa | Concept notes accepted on a rolling basis | |
| Other Canadian | University of Toronto Institutional Strategic Initiatives (ISI) | From ,000-0,000 per year for up to 3 years. | ISI awards are intended to establish research capacity in high-priority areas, with the goal of realizing transformational impacts on issues of societal importance. Proposed investigator-initiated initiatives must meet the following key criteria: 1) Address a significant challenge and associated research questions that requires an interdisciplinary approach; 2) Matching funds secured from three or more Academic Divisions; 3) Path to sustainability demonstrated by a clear opportunity for external funding. | Ongoing | |
| Other Canadian | Collaboration Opportunities: National Research Council Canada (NRC) Challenge Programs | -- | The NRC offers potential opportunities for collaboration in the following areas: - Aging in Place - Artificial Intelligence for Design - Disruptive Technology Solutions for Cell and Gene Therapy - High-throughput and Secure Networks - Pandemic Response Potential collaborators can register their interest to work with NRC on the Challenge Programs website. | Ongoing | |
| Other Canadian | Rare Diseases: Models & Mechanisms Network Catalyst Grants | 25000 | The Rare Diseases: Models & Mechanisms Network has been established to catalyze connections between people discovering new genes in patients with rare diseases, and basic scientists who can analyze equivalent genes and pathways in model organisms. Catalyst Grants fund projects that will allow rapid confirmation of potentially disease-causing genes, and fuel pilot studies to improve understanding of how specific gene mutations cause disease. This application is intended for investigators who wish to link their gene discovery to a model organism researcher. | Continuous. | |
| Other Canadian | Government of Canada: CanExport for Innovators | Maximum of ,000 | Specifically designed to promote and enhance Canada's international innovation efforts. Eligible expenses may include international and local travel, accommodation, meals, meeting costs, legal fees to support formalized partnerships, and other costs related to international collaboration. Applications must be submitted at least 8 WEEKS prior to the anticipated start date of the activities. | Continuous | |
| Other Canadian | Weston Brain Institute: Early Phase Clinical Trials: Canada | Up to ,500,000 per project for up to 4 years | Funding for clinical trials and/or clinical trial sub-studies with excellent preliminary data. | Rolling deadline | |
| Other Canadian | Physicians' Services Incorporated (PSI) Foundation: Health Research Grant & New Investigator Grant | Health Research Grant: Up to 0,000 for 3 years. New Investigator Grant: Up to 0,000 for 3 years. | Areas of Support: clinical research, medical education research, health systems research. Applicant must be a College of Physicians and Surgeons of Ontario licensed MD. New Investigators must be within five years of their first academic appointment. | Rolling deadline | |
| Other Canadian | Telus Funds | Various | For entertaining and engaging web series with the potential to positively impact families and friends providing care for loved ones struggling with a health condition. | Various | |
| Other Canadian | Ontario Centre of Innovation (OCI) Voucher for Innovation and Productivity (VIP) Program | Minimum of ,000 up to a maximum of 0,000 per year towards the direct costs of research (Industry Partner contribution has to be minimum of 1:1 cash match to the OCE contribution, where at least 50% must be spent at the post-secondary institution.) | This program helps companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions and research hospitals. VIP projects are intended to generate economic benefit for companies in Ontario (including job creation/retention, new revenue generation, investment attraction, cost savings, value chain development), in the short-to-medium term (e.g. within three years of project completion). If you are interested, please contact Samar Saneinejad (Samar.Saneinejad@unityhealth.to). | No Deadline | |
| International | Pre-Announcemement: FY23 Peer Reviewed Orthopaedic Research Program (PRORP): Various Opportunities | Please see individual funding opportunity description. | • Applied Research Award: Supports applied research applications focused on advancing optimal treatment and restoration of function for military personnel with musculoskeletal injuries sustained during combat or Service-related activities. Value: Up to USD 0,000 for up to 3 years. • Clinical Trial Award: Supports rapid implementation of clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries or non-battle injuries that significantly impact unit readiness and return-to-duty/work rates. Value: Up to USD .5M for up to 4 years; Up to .0M for up to 4 years for the Collaborative Care Option. • Clinical Translational Research Award: Supports high-impact and/or emerging research that may or may not be ready for a full-scale, randomized, controlled clinical trial. Funding must support clinical research studies involving humans. Value: Up to USD .5M for up to 4 years. | TBA | |
| International | Thrasher Research Fund: E.W. "Al" Thrasher Awards | Up to USD 0,000. | Ideal applications address significant health problems, offering the potential for practical solutions to these problems. Typically, the primary outcome is a health outcome in children. Solutions should be innovative and have the potential for broad applicability with low barriers to implementation. Projects with a shorter distance to clinical applicability are given priority. Hypothesis-driven research is critical; exploratory, or hypothesis-generating research will not be competitive. For projects focused on improving disease diagnosis, please ensure that there are well researched, effective treatment options available to patients upon diagnosis. | Concept Paper: January 17, 2023; July 18, 2023. Full Proposal (by invitation): April 21, 2023; October 20, 2023. | |
| International | Pfizer Global Medical Grants (GMG) Quality Improvement Request for Proposals (RFP): Optimizing Women’s Health Conditions in Canada | Up to $30,000. | This seeks to support Quality Improvement (QI) initiatives focused on menopause, uterine fibroids, endometriosis, and/or contraception in areas including improving the detection/diagnosis, optimizing treatment and/or management, and improving the dialogue between healthcare professionals and patients. QI projects should encompass systematic and continuous actions that directly impact patient care and include measurable outcomes via methodologically rigorous methods | July 19, 2023. | |
| International | Pfizer Global Medical Grants (GMG) Independent Medical Education Request for Proposals (RFP): Women’s Health Education Grants | Up to $15,000. | This seeks to encourage grant applications for independent educational activities focused on increasing health care professional (HCP) awareness and expertise of menopause, uterine fibroids, endometriosis, and/or contraception. Potential applicants are encouraged to identify and address the educational needs of healthcare professionals in Canada, including Primary Care Providers, Allied Healthcare Professionals (e.g., nurse practitioners, physician assistants, pharmacists), and Specialists, to increase awareness and expertise of menopause, uterine fibroids, endometriosis, and/or contraception | July 19, 2023. | |
| International | Alzheimer's Drug Discovery Foundation (ADDF): Prevention RFP | Up to ,000,000 for clinical trials based on stage and scope of research. Multi-year duration. | This supports studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Please note: Anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) and cholinesterase inhibitor proposals will not be considered. | Letter of Intent: February 3, 2023; May 19, 2023; September 29, 2023. Invited Full Proposal: April 7, 2023; July 28, 2023; December 1, 2023. | |
| International | Biogen: Various Opportunities | -- | Biogen considers requests in Biosimilars (Dermatology, Gastroenterology, Ophthalmology, Rheumatology), Multiple Sclerosis, and Spinal Muscular Atrophy in these areas: • Medical Education: Supports independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited. • Patient Education: Supports independent educational activities for patients or caregivers. • General Grant: Supports a project or program that does not fit any of the other defined grant categories. | April 15, August 15, November 1. | |
| International | American Psychological Foundation (APF): Various Opportunities | Please see individual funding opportunity description. | • APF/Division 39 Grant: Supports efforts in education, research, and service that advance and encourage the field of psychoanalysis. Value: USD ,000. • Marian R. Stuart Grant: Support to to further the research, practice, or education of an early career psychologist on the connection between mental and physical health, particularly for work that contributes to public health. Applicant must be an early career researcher (no more than 10 years postdoctoral). Value: Up to USD ,000. • Visionary Grants: Support research, education, and intervention projects and programs that use psychology to solve social problems in the priority areas listed on the Visionary Grants webpage. Applicants must be a graduate student or early career researcher (no more than 10 years postdoctoral). Value: Up to USD ,000. • Wayne F. Placek Grants: Support empirical research from all fields of the behavioral and social sciences on any topic related to lesbian, gay, bisexual, or transgender issues. Graduate students and early career researchers are encouraged to apply. Value: Up to ,000. NOTE: The above list includes those grants valued at least USD ,000. Please see the APF website for other opportunites valued less than USD ,000. | • APF/Division 39 Grant: August 31, 2023. • Marian R. Stuart Grant: July 1, 2023. • Visionary Grants: April 1, 2023. • Wayne F. Placek Grants: May 1, 2023. | |
| International | Lung Cancer Research Foundation (LCRF): Various Opportunities | Various values depending on opportunity. | • Leading Edge Research Grant Program: This funds innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, early detection, disparities, and social determinants of health research. Applicant must have less than 10 years’ experience since their initial faculty appointment. Value: USD ,000 per year for 2 years. Deadlines: Letter of Intent: March 10, 2023; Full proposal (by invitation): May 31, 2023. • Minority Career Development Award (CDA) in Lung Cancer: This supports early-stage scientists from underrepresented groups working in lung cancer and working in diverse areas of research including basic, clinical, translational, disparities, and social determinants of health research. Investigators must be from racial or ethnic groups that are underrepresented in health-related sciences and biomedical research and must be an assistant professor within 10 years of completing their MD and/or PhD degrees. Value: USD ,000 per year for 2 years. Deadline: May 31, 2023. • Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer: Supports research projects that facilitate or advance the understanding and characterization of pre-neoplasia or approaches for early detection of lung cancer. Work supported through this mechanism addresses important questions in non-small cell and small cell lung cancer. Applicant must have less than 10 years’ experience since their initial faculty appointment. Value: USD ,000 per year for 2 years. Deadlines: Letter of Intent: March 10, 2023; Full proposal (by invitation): May 31, 2023. • Research Grants on Understanding Resistance in Lung Cancer: This focuses on understanding development, prevention, and therapy of resistance by supporting research projects that are identifying, characterizing, treating, or preventing resistance to therapies in lung tumor cells, tissues, mouse models, and/or patients. Value: USD ,000 per year for 2 years. Deadlines: Letter of Intent: March 10, 2023; Full proposal (by invitation): May 31, 2023. | • Leading Edge Research Grant Program: Letter of Intent: March 10, 2023; Full proposal (by invitation): May 31, 2023. • Minority Career Development Award (CDA) in Lung Cancer: May 31, 2023. • Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer: Letter of Intent: March 10, 2023; Full proposal (by invitation): May 31, 2023. • Research Grants on Understanding Resistance in Lung Cancer: TLetter of Intent: March 10, 2023; Full proposal (by invitation): May 31, 2023. | |
| International | American Society of Colon and Rectal Surgeons (ASCRS) Research Foundation: Various Opportunities | Various values depending on opportunity | • Research in Robotic Surgical Technology Grants: This is for research interests specifically germane to robotic surgical technology in the field of colon and rectal surgery. Value: USD ,000 for 1 year; Up to USD 0,000 for 1 year for collaborative proposals that include 2 or more institutions. • International Fellowship Grants: This grant will focus on providing support to clinical investigators in the United States or Canada who would like to participate in research outside the United States or Canada. Value: USD ,500 for 1 year. • General Surgery Resident Research Initiation Grants: Applicants must be General Surgical Residents or recent (within 2 years) Graduates of a US or Canadian approved General Surgery Training Program. Value: USD ,000 for 1 year. | August 15, 2023. | |
| International | The ZOLL Foundation: Seed Grants | Typically in the USD ,000-,000 range. | This invites studies in the fields of resuscitation or acute critical care that aim to improve practices, prevent patient deterioration, reduce mortality and morbidity, or address some other aspect of enhancing care. Grant applicants should be newer researchers, ideally recommended by a more established investigator. | Deadlines: March 31, 2023; September 30, 2023. | |
| International | CHEST Foundation 2023 Requests for Proposals | Various values depending on funding opportunity. | • CHEST Foundation Pulmonary Medicine Research Grant: Applications must advance the understanding of pulmonary medicine and be clinically relevant with a focus in pulmonary fibrosis. Projects must also demonstrate how they will have a positive impact on the lung health of a community. Value: USD 0,000 over 3 years. • Research Grants (Various Topics): Support projects that will lead to breakthroughs in the treatment of chest diseases and patient care. The following grants are available: Community Service, COPD, COVID-19, Medical Education, Venous Thromboembolism, Women’s Lung Health Disparities, Young Investigator. Value: Varies by grant from USD ,000 to ,000 for 1 year. NOTE: Applicants for all grants must have CHEST membership at time of application. | April 10, 2023. | |
| International | Preeclampsia Foundation Vision Grants | Up to USD ,000. | Vision Grants are intended to provide initial funding for novel, innovative research by promising young investigators that will advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy. Applicants must be untenured faculty within 10 years of completing their terminal research degree or within 10 years of completing their medical residency and have yet to receive significant external research funding. | April 14, 2023. | |
| International | Osteosynthesis and Trauma Care Foundation (OTCF) Research Grants | Up to USD ,000 for up to 2 years. | This is to stimulate scientific studies in support of evidence-based research in surgical practice. Support of basic, pre-clinical, biomechanical, experimental, and translational research is the immediate aim of the program. A trauma or orthopedic surgeon must serve as either the principal or co-principal investigator. NOTE: Candidates and institutions may receive only one OTC Grant in each year. | April 15, 2023. | |
| International | International Center for Responsible Gaming (ICRG) 2023 Grants Program | Large Grants: Up to USD ,000 per year for up to 2 years. Seed Grants: Up to USD ,000 for 1 year. | Large Grants: Researchers are invited to apply for a Large Grant focused on gambling disorder or responsible gambling. Seed Grants: Seed Grants support of a variety of research activities, exploring the etiology, prevention and treatment of gambling disorder, and the development and evaluation of responsible gambling strategies, such as: Pilot and feasibility studies; Secondary analysis of existing data; Small, self-contained research projects; Development of research methodology; Development of new research technology. | Large Grants: Letter of Intent: April 3, 2023; Full Application (by invitation): July 14, 2023. Seed Grants: May 1, 2023. | |
| International | American Society of Hematology (ASH) Junior Faculty Scholar Award | Up to USD 0,000 for 2 or 3 years | This is for applicants who hold independent faculty level positions. It provides partial salary or other research support during that critical period required for completion of training and achievement of status as an independent investigator. As of the letter of intent deadline, applicants must have between eight and 13 years of research experience following completion of their terminal degree (including research performed during fellowship but excluding clinical fellowship time), be an ASH member in good standing, and have at least 75% protected time for research. | Letter of Intent: May 1, 2023 Application (by invitation): August 1, 2023. | |
| International | Mark Foundation for Cancer Research: Emerging Leader Award | USD 0,000 per year for 3 years | These support innovative cancer research from the next generation of leaders. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio. Proposed projects must not be supported by other sources of funding. Applicants must be three to eight years from the start of an independent faculty research appointment as of December 31, 2023 (i.e., the official start date of the appointment must fall within the calendar years 2015-2020). Exceptions due to prolonged medical or family leave will be considered on a case-by-case basis. | Letter of Intent: May 1, 2023. Application (by invitation): July 24, 2023. Virtual Interview: October, 2023. | |
| International | Foundation for Physical Medicine & Rehabilitation (Foundation for PM&R): Various Opportunities | • Encompass Midcareer Investigator Research Grant: USD ,000 for 1 year. • Scott Nadler PASSOR Musculoskeletal Research Grant: USD ,000. • Pain Management and Spine Care Research Grant: USD ,000 | • Encompass Midcareer Investigator Research Grant: For research in topics related to the field of physical medicine and rehabilitation; it is to be used as seed money for new research projects that extend an established investigator’s work in new directions. Eligible applicants include any physiatrist or faculty member in a division or department of physical medicine and rehabilitation who is at least 5 and not more than 20 years post-completion of a terminal degree and subsequent training program. At least one member of the research team (PI or co-investigator) must be a member of the American Academy of PM&R (AAPM&R) and/or the Association of Academic Physiatrists (AAP). Value: USD ,000 for 1 year. • Scott Nadler PASSOR Musculoskeletal Research Grant: This is a seed grant for research in topics related to musculoskeletal rehabilitation in the field of physical medicine and rehabilitation. Applicant and/or at least one co-investigator must be members of the AAPM&R and/or the AAP. Value: USD ,000. • Pain Management and Spine Care Research Grant: This is a seed grant for research in topics related to pain medicine and spine care in the field of physical medicine and rehabilitation. Applicant and/or at least one co-investigator must be members of the AAPM&R and/or the AAP. Value: USD ,000. | May 1, 2023. | |
| International | American Psychoanalytic Association (APsaA) Fund for Psychoanalytic Research: Research Grant | USD ,000 for 1 year. | This is for a specific project building upon psychoanalytic principles or directly investigating the process and/or outcome of psychoanalytically informed treatments. The Fund conceives of psychoanalytic research along the broadest lines, including: scholarly and empirical investigative contributions that can advance knowledge of psychoanalytic theory, practice, and links between psychoanalysis and neighboring disciplines such as developmental psychology or neuroscience. | May 1 and December 31 of each year. | |
| International | JDRF Strategic Research Agreements | The budget and duration of funding are variable. | These provide research funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in Type 1 diabetes research. The Strategic Research Agreement is a partnership between Investigator(s) and JDRF Scientists to help address roadblocks and accelerate JDRF's mission through support of cutting-edge scientific investigation. Further, this mechanism embodies cooperative development of a research plan, interim quarterly reporting on milestones and interaction with JDRF scientists prior to and during the award period. | May 3, 2023. | |
| International | MIT Solve/shift7: Indigenous Communities Fellowship Challenge | USD ,000 with potential for additional funds. | MIT Solve is a marketplace for social impact innovation with a mission to drive innovation to solve world challenges. This is open to all innovators supporting community-based solutions by and for Indigenous communities across the United States and Canada. Solve seeks solutions that will: Promote culturally informed mental and physical health and wellness services for Indigenous community members. | May 9, 2023. | |
| International | Ulla-Carin Lindqvists Stiftelse Grants for research on amyotrophic lateral sclerosis | Not specified. Allocation is ~5M SEK (~0K CAD) on an annual basis. | Ulla-Carin Lindquist Foundation for ALS-Research funds research and information spreading projects in Sweden and abroad. | August 1, 2023. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY23 Lung Cancer Research Program (LCRP) | • Career Development Award: Up to USD 5,000 for up to 3 years. • Concept Award: Up to USD 0,000 for up to 1 year. • Idea Development Award:Up to USD 5,000 for up to 3 years. • Translational Research Award: Funding Level 1: Up to USD 0,000 for up to 3 years; Funding Level 2: Up to USD ,200,000 for up to 4 years. | • Career Development Award: Supports early-career, independent researchers to conduct research under the mentorship of an experienced lung cancer researcher. Applicant at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment (or equivalent). Value: Up to USD 5,000 for up to 3 years. Deadlines: Pre-Application: May 2, 2023; Application: May 23, 2023. • Concept Award: Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer. Value: Up to USD 0,000 for up to 1 year. Deadlines: Pre-Application: May 2, 2023; Application: May 23, 2023. • Idea Development Award: Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research. Value: Up to USD 5,000 for up to 3 years. Deadlines: Pre-Application: May 10, 2023; Application: August 3, 2023. • Translational Research Award: Supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Value: Funding Level 1: Up to USD 0,000 for up to 3 years; Funding Level 2: Up to USD ,200,000 for up to 4 years. Deadlines: Pre-Application: May 10, 2023; Application: August 3, 2023. | • Career Development Award: Pre-Application: May 2, 2023; Application: May 23, 2023. • Concept Award:Pre-Application: May 10, 2023; Application: August 3, 2023. • Translational Research Award: Pre-Application: May 10, 2023; Application: August 3, 2023. | |
| International | International Brain Research Organization (IBRO) Rising Stars Awards | TBD. 80% of the grant will be awarded in advance, and the remaining 20% upon completion and submission of the associated grant report | This program aims to increase the successful transition and retention of diverse, early career neuroscientists into academic positions by providing funds to make a significant difference in their research endeavors. It supports the research needs of early career faculty from diverse and/or underrepresented backgrounds (racial/ethnic minorities, sexual orientation, disability, etc) and early career faculty who do not have substantial start-up funds or grant support from other agencies. Applicants should be within the first five years of their initial faculty appointment. Preference will be given to those who have not previously received, nor expect to receive, substantial support from other sources. | October 11, 2023. | |
| International | Alzheimer's Drug Discovery Foundation (ADDF): Various Opportunities | • Drug Development RFP: Up to USD ,000,000; multi-year. • Neuroimaging and CSF Biomarker RFP: Up to USD 0,000 for 1 year. • Prevention RFP: Value: Up to USD ,000,000 for clinical trials; multi-year. • Peripheral Biomarkers RFP: Not specified. • Digital Biomarkers RFP:Not specified. | • Drug Development RFP: This prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. Amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered. Value: Up to USD ,000,000; multi-year. • Neuroimaging and CSF Biomarker RFP: This is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. Novel biomarkers of neuroinflammation, synaptic integrity, autophagy and TDP-43 are high priority. Value: Up to USD 0,000 for 1 year. • Prevention RFP: Supports studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Value: Up to USD ,000,000 for clinical trials; multi-year. Deadlines: Letter of Intent: February 3, 2023; May 19, 2023; September 29, 2023. Invited Full Proposal: April 7, 2023; July 28, 2023; December 1, 2023 • Peripheral Biomarkers RFP: Blood and other peripheral markers, including saliva, urine, and ocular biomarkers are encouraged. The development of CSF and neuroimaging biomarkers will not be considered for this program; however, we encourage the use of these modalities to validate proposed biomarkers. Value: Not specified. • Digital Biomarkers RFP: A variety of digital platforms such as portables, sensors, or software are encouraged. The proposed platform should have the potential to be easily deployed at scale. Passive approaches to data collection are encouraged. Value: Not specified. | • Drug Development RFP, Neuroimaging and CSF Biomarker RFP, Prevention RFP: Letter of Intent: February 3, 2023; May 19, 2023; September 29, 2023. Invited Full Proposal: April 7, 2023; July 28, 2023; December 1, 2023 • Peripheral Biomarkers RFP, Digital Biomarkers RFP: Rolling. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY23 Amyotrophic Lateral Sclerosis Research Program (ALSRP) | This is anticipated to provide funding for the ALSRP to support the development of effective treatments for amyotrophic lateral sclerosis (ALS). • Pilot Clinical Trial Award: Up to USD ,000,000 for up to 3 years; Clinical Care Tier: Up to USD ,000,000 for up to 3 years. • Clinical Biomarker Development Award: SUp to USD 0,000 for up to 2 years. • Therapeutic Development Award: Up to USD ,500,000 for up to 3 years. • Therapeutic Idea Award: Up to USD 0,000 for up to 2 years; Biomarker Option: Up to USD 0,000 for up to 2 years. | This is anticipated to provide funding for the ALSRP to support the development of effective treatments for amyotrophic lateral sclerosis (ALS). • Pilot Clinical Trial Award: Supports exploratory clinical trials of novel therapeutics or devices to demonstrate feasibility and inform the design of more advanced trials in ALS. Clinical Care Tier: For applications not investigating a novel therapeutic, but proposing a clinical trial to optimize aspects of established ALS multi-disciplinary care. • Clinical Biomarker Development Award: Supports development or improvement of clinical biomarkers to enrich clinical trials in ALS. • Therapeutic Development Award: Supports secondary preclinical validation and Investigational New Drug (IND)-enabling studies of therapeutics for ALS. • Therapeutic Idea Award: Supports highly innovative, hypothesis-driven preclinical therapeutic development in ALS. Projects focusing primarily on investigating ALS pathophysiology, without consideration of therapeutic development, are outside the scope of this award mechanism. Biomarker Option: For applications that include development of biomarkers in parallel to the main therapeutic effort. | Pre-Application: April 13, 2023. Application: July 13, 2023. | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY23 Multiple Sclerosis Research Program (MSRP) | The CDMRP has pre-announced the following opportunities. Please see details of these at the MSRP link. • Clinical Trial Award: Funding Level 1: Up to USD .6M total costs for up to 3 years. Funding Level 2: Up to USD .5M total costs for up to 4 years. • Early Investigator Research Award: Up to USD 0,000 total costs for up to 2 years. • Exploration - Hypothesis Development Award: Up to USD 0,000 total costs for up to 2 years. • Investigator-Initiated Research Award: Up to USD .0M total costs for up to 3 years. | The CDMRP has pre-announced the following opportunities. Please see details of these at the MSRP link. • Clinical Trial Award: Funding Level 1 supports early-phase, proof-of-principle clinical trials to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this Funding Level. Value: Up to USD .6M total costs for up to 3 years. Funding Level 2 supports larger-scale clinical trials at phase 1 or 2 that seek to show preliminary evidence of safety or efficacy (benefit on clinical or paraclinical outcomes) in relevant patient populations. Value: Up to USD .5M total costs for up to 4 years. • Early Investigator Research Award: The applicant must be involved in a postdoctoral training or medical residency program and possess at least 1 and up to 4 years continuous postdoctoral research experience; and commit at least 50% of their effort towards the project. Value: Up to USD 0,000 total costs for up to 2 years. • Exploration - Hypothesis Development Award: Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field. Value: Up to USD 0,000 total costs for up to 2 years. • Investigator-Initiated Research Award: Supports highly rigorous, high-impact research with the potential to make an important contribution to MS research and/or patient care. Clinical trials not allowed. Value: Up to USD .0M total costs for up to 3 years. | TBA | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY23 Breast Cancer Research Program (BCRP) | Please see individual funding opportunity description. | The BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations. • Breakthrough Award Levels 1 and 2: Value: Funding Level 1: Up to USD 0,000 or up to USD 0,000 with the Partnering PI Option for up to 3 years; Funding Level 2: Up to USD million for up to 3 years (up to USD .5 million for Population Science and Prevention Studies for up to 4 years). With the Partnering PI Option, up to USD .5 million for up to 3 years (or up to USD million for Population Science and Prevention Studies for up to 4 years). Deadlines: Pre-Application: March 28, 2023; Application: April 11, 2023. • Era of Hope Scholar Award: Value: Up to USD million for up to 4 years. Deadlines: Pre-Application: March 28, 2023; Application: April 11, 2023; Recommendation Letters: April 14, 2023. • Clinical Research Extension Award: Value: Up to USD million for up to 4 years; Up to USD million for up to 4 years. Deadlines: Pre-Application: March 28, 2023; Application: April 11, 2023. • Transformative Breast Cancer Consortium Development Award: Value: Up to USD 0,000 for up to 1 year. Deadlines: Pre-Application: March 28, 2023; Application: April 11, 2023. • Transformative Breast Cancer Consortium Award: Value: Up to USD million for up to 4 years. Deadlines: Pre-Application: March 29, 2023; Application: June 28, 2023. • Breakthrough Award Levels 3 and 4: Value: Funding Level 3: Up to USD million or up to USD million with the Partnering PI Option for up to 4 years; Funding Level 4: Up to USD million for up to 4 years. Deadlines: Pre-Application: March 29, 2023; Application: June 28, 2023. • Innovator Award: Value: Up to USD million for up to 4 years. Deadlines: Pre-Application: March 29, 2023; Application: June 28, 2023; Recommendation Letters: June 30, 2023. | Deadlines vary by funding opportunity. | |
| International | US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY23 Peer Reviewed Medical Research Program (PRMRP) | • Clinical Trial Award: 1) Clinical trial only: funding limit not defined; up to 4 years; 2) Planning Phase with clinical trial: Up to USD 0,000 for the planning phase and up to 18 months for the planning phase; up to 4 years for the clinical trial. • Discovery Award: Up to USD 0,000 for up to 2 years. • Focused Program Award: Up to USD .2 million for up to 4 years. • Investigator-Initiated Research Award: Up to USD .6 million or up to USD million with the Partnering PI Option for up to 4 years. • Lifestyle and Behavioral Health Interventions Research Award: Up to USD million for up to 4 years. • Technology/Therapeutic Development Award: Funding Level 1: Up to USD million for up to 4 years; Funding Level 2: Up to USD million for up to 4 years. | Applications must address one or more of the Strategic Goals within the potential FY23 PRMRP Topic Areas listed in the funding opportunities: Autoimmune Disorders and Immunology, Cardiovascular Health, Hemorrhage Control and Blood Products, Infectious Diseases, Internal Medicine, Neuroscience, Orthopaedic Medicine, Rare Diseases and Conditions, Respiratory Health. • Clinical Trial Award: Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials. • Discovery Award: Supports the exploration of a highly innovative new concept or untested theory. • Focused Program Award: Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal/question. • Investigator-Initiated Research Award: Supports research that will make an original and important contribution to the field of research or patient care in the Topic Area(s) of interest. • Lifestyle and Behavioral Health Interventions Research Award: Supports the development, evaluation, and implementation of therapies, technologies, and innovations that will enhance patient experience and improve outcomes. • Technology/Therapeutic Development Award: Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, and/or quality of life. | • Clinical Trial Award: Pre-Application: April 12, 2023; Application: July 19, 2023. • Discovery Award: Pre-Application: March 29, 2023; Application: April 26, 2023. • Focused Program Award: Pre-Application: April 12, 2023. Application: July 19, 2023. • Investigator-Initiated Research Award: Pre-Application: April 19, 2023; Application: May 31, 2023. • Lifestyle and Behavioral Health Interventions Research Award: Pre-Application: April 19, 2023; Application: May 31, 2023. • Technology/Therapeutic Development Award: Pre-Application: April 19, 2023; Application: May 31, 2023. | |
| International | Solving Kids' Cancer Therapeutic Development Initiative (TDI) | ,000 to 0,000 USD for up to 2 years. | Solving Kids' Cancer is a nonprofit organization with a track-record of funding novel clinical research for children diagnosed with high-risk solid tumors specifically neuroblastoma, brain tumors and sarcomas. The TDI's goal is to support innovative early phase clinical studies that are high on the risk/reward spectrum. Priority is given to proposals that introduce novel therapeutic agents and modalities and have a strong potential to improve treatment outcomes. | Preliminary Proposal Deadline: Rolling | |
| International | Össur Orthopaedic Research Grant Program | -- | This provides funding for scientific inquiry in the areas of lower extremity biomechanics, dynamic/active rehabilitation, ortho biologics, functional bracing, clinical patient outcomes, and, related healthcare economics. | Rolling Deadline | |
| International | Gateway for Cancer Research | GFCR Grant Program: USD 0,000 to .5 million for 2-5 years GFCR Integrative Program:USD 0,000 to .5 million for 2-5 years. SIO / Gateway Integrative Research Grant Program: Value: USD 0,000 to .5 million for 2-5 years. | Gateway funds Phase I and II patient-centered cancer clinical trials that have the potential to shift the paradigm for standard of care, focusing on the following priority research areas: Biomarkers/Molecular Markers (genomic or proteomic); Gene Therapy; Histology Agnostic/Basket Trial; Immunotherapy; Targeted Therapies. Focus is on the following therapeutic areas: New Investigational Therapies; Novel Use or Approach; Precision Medicine; Integrative Medicine. • GFCR Grant Program: Funds early phase clinical trials for cancers of all types at renowned institutions around the world. • GFCR Integrative Program: Funds integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment. • SIO / Gateway Integrative Research Grant Program: Funds integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment. • GFCR Decentralized (DCTI) Grant Program: Leverages site-less, technology-informed trials, with the objective of bringing clinical trials directly to patients doorsteps. | • GFCR Grant Program: Rolling Deadline • GFCR Integrative Program: Rolling Deadline • SIO / Gateway Integrative Research Grant Program: Rolling Deadline • GFCR Decentralized (DCTI) Grant Program: Rolling Deadline | |
| International | Aesculap Implant Systems Investigator-Initiated Study Program (IIS) | Dependent on the type of research and availability of support. | This supports researchers interested in conducting studies of their own design, which promotes the advancement of medical and scientific knowledge related to Aesculap's products and therapeutic areas of focus: Neurosurgery; Surgical Technologies; Closure Technologies; Orthopaedics; Spine; Biologics. | Continuous | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY23 Rare Cancers Research Program (RCRP) | Value: Up to USD $800,000 for up to 4 years. | CDMRP will follow the definition of rare cancer as an incidence of six or fewer cases per 100,000 people per year in the US. Concept Award: Supports innovative, high-risk/high-reward research. Proof-of-concept is the anticipated outcome. Must address one or more of the following FY23 Focus Areas: Biology and Etiology; Research Model; and/or Therapy. Value: Up to USD 0,000 for up to 2 years. Idea Development Award: Preliminary data with disease-specific rationale to support the feasibility of the research hypotheses and research approaches are required. Must address one or more of the following FY23 Focus Areas: Biology and Etiology; Research Model; and/or Therapy. Value: Up to USD 0,000 for up to 3 years. Resource and Community Development Award: Supports platform development or infrastructure that can be applied to multiple rare cancers. Emphasis on research resources development to facilitate collaboration and information sharing among stakeholders such as researchers, patients, family members, caregivers, clinicians, and other members of the rare cancers community. | TBA | |
| International | Pre-Announcement: United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP) FY23 Spinal Cord Injury Research Program (SCIRP): Various Opportunities | • Clinical Trial Award: Up to USD .0M for up to 4 years; Early-Career Partnering PI Option, up to USD .1M for up to 4 years. • Clinical Translation Research Award: Up to USD .25M for up to 3 years; Early-Career Partnering PI Option, up to USD .35M for up to 3 years. • Translational Research Award: FUp to USD .25M for up to 3 years; Early-Career Partnering PI Option, up to USD .35M for up to 3 years. • Investigator-Initiated Research Award: Up to USD @.50M for up to 3 years; Early-Career Partnering PI Option, up to USD @.60M for up to 3 years. | Applications submitted to the FY23 SCIRP must address one or more of the Focus Areas listed on the opportunities website. • Clinical Trial Award: Funds the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of spinal cord injury (SCI). Value: Up to USD .0M for up to 4 years; Early-Career Partnering PI Option, up to USD .1M for up to 4 years. • Clinical Translation Research Award: Supports high-impact and/or new/emerging clinical research that may not be ready for a full-scale clinical trial. Value: Up to USD .25M for up to 3 years; Early-Career Partnering PI Option, up to USD .35M for up to 3 years. • Translational Research Award: Funds studies that accelerate the movement of promising ideas in SCI research into clinical applications. Value: Up to USD .25M for up to 3 years; Early-Career Partnering PI Option up, to USD .35M for up to 3 years. • Investigator-Initiated Research Award: Funds research that has the potential to make an important contribution to SCI research, patient care, and/or quality of life. Studies focused exclusively on target identification are discouraged. Value: Up to USD @.50M for up to 3 years; Early-Career Partnering PI Option, up to USD @.60M for up to 3 years. | TBA | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY23 Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) | • Clinical Trial Award: Up to USD 0,000 for up to 3 years; Funding Level 2: Up to USD .0M for up to 4 years; Funding Level 3: Up to USD .0M for up to 4 years. • Focused Program Award: Up to USD .0M for up to 4 years. • Investigator-Initiated Research Award: SUp to USD 0,000 for up to 3 years. • Translational Research Award: Up to USD .0M for up to 4 years. • Health Services Research Award: Up to USD .5M for up to 4 years. | Applications submitted to the FY23 TBIPHRP must address one or more of the Focus Areas listed on the opportunities website. • Clinical Trial Award: Supports clinical trials for pharmacological (e.g., biologics, drugs) and non-pharmacological (e.g., devices, psychotherapy) interventions. Value: Funding Level 1: Up to USD 0,000 for up to 3 years; Funding Level 2: Up to USD .0M for up to 4 years; Funding Level 3: Up to USD .0M for up to 4 years. • Focused Program Award: Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal. Value: Up to USD .0M for up to 4 years. • Investigator-Initiated Research Award: Supports research with the ability to make an original and important contribution to research and/or patient care. Value: Up to USD 0,000 for up to 3 years. • Translational Research Award: Supports the translation of promising research into clinical application (i.e., preclinical to clinical translation). Value: Up to USD .0M for up to 4 years. • Health Services Research Award: Bridges the gap between research, practice, and policy by building a knowledge base on how interventions and clinical practices/guidelines and policies can be deployed to targeted populations at the appropriate time at the point of need. Value: Up to USD .5M for up to 4 years. | TBA | |
| International | Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY23 Combat Readiness-Medical Research Program (CRRP) Translational Research Award | Up to USD .1M total costs for up to 2 years. | Proposed research must address at least one of the FY23 CRRP Focus Areas: Solutions to enhance combat care delivery throughout the far-forward environment; Wound care solutions for complex trauma and tissue regeneration that span the operational medical care continuum or roles of care (e.g., acute through chronic care); Solutions to enhance Warfighter readiness. Please see Focus Area details at the CRRP webpage. | TBA | |
| International | Bausch + Lomb Grants | -- | • Educational Grants: These contribute to the improvement of patient care and advances in the use of healthcare products. Grand-rounds, lectures, symposiums and workshops are funded to educate medical students, university faculty, physicians, nurse practitioners, optometrists, ophthalmologists, allied health professionals, optical research scientists and associations of optometry and ophthalmology about improvements in ocular health. • Independent Research Grant: These empower the global research community to develop new treatments and technological advancements in ocular health. Research Grants have been funded by to improve consumers’ standard of care, efficacy, patient satisfaction, safety and vision performance. | Rolling submission. Allow 6-12 weeks for proposal review and decision. | |
| International | Pre-Announcement: United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP): FY23 Peer Reviewed Alzheimer’s Research Program (PRARP): Various Opportunities | • Transforming Research Award: Up to USD .0M total costs for up to 3 years. • Transforming Diagnosis Award: Up to USD .5M total costs for up to 4 years. • Transforming Care Award: Up to USD .0M total costs or up to USD .0M total costs with Career Initiation and Transition Partnering Option (CITPO) for up to 4 years. | Applications submitted to the FY23 PRARP must have a translational/transition component, community engagement, and address one of the following Focus Areas listed on the opportunity website. • Transforming Research Award: Within the Prevention and Risk Reduction Focus Area, supports transformative research with near term, high impact outcomes. Value: Up to USD .0M total costs for up to 3 years. • Transforming Diagnosis Award: Within the Diagnostic, Environmental, and Prognostic Factors Focus Area, supports research to transform diagnosis and prognosis to better determine the trajectory, long-term outcomes, and impact of AD/ADRD following military service and/or TBI. Value: Up to USD .5M total costs for up to 4 years. • Transforming Care Award: Within the Individual, Caregiver, and Family Support Focus Area, supports research that prioritizes the individual with AD/ADRD, their care partner/caregiver, and/or both that clearly demonstrates feasibility and identifies a realistic approach to scaling and implementation. “Care” does not include medical care (such as medical interventions administered by a physician). Value: Up to USD .0M total costs or up to USD .0M total costs with Career Initiation and Transition Partnering Option (CITPO) for up to 4 years. | TBA. | |
| NIH | NIH Notice of Special Interest (NOSI): Opportunities for HIV Cure Interventions at the Time of ART Initiation | -- | The scientific objective is to support projects to explore HIV cure approaches administered during active HIV/SHIV/SIV infection, prior to or around the time of ART initiation, before viral loads are completely suppressed, or after an analytical treatment interruption to potentially enhance the ongoing immune response and prevent additional reservoir seeding. The curative approaches studied should be experimental, innovative, and not yet approved by the FDA or a foreign regulatory agency for an HIV indication. | This notice applies to due dates on or after January 7, 2023 and subsequent receipt dates through September 7, 2025. | |
| NIH | NIH Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional) | -- | The primary objective is to move Digital Therapeutics (DTx) to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for Substance Use Disorders (SUDs). Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications. | April 6, 2023; August 4, 2023; December 6, 2023. | |
| NIH | NIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) | -- | This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address National Institute of Mental Health (NIMH) strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. | Deadlines: February 16, 2023; June 16, 2023; October 16, 2023; February 16, 2024; June 16, 2024; October 16, 2024; February 16, 2025. | |
| NIH | NIH HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed) | _ | The focus is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. | February 2, 2023; June 2, 2023; October 4, 2023; February 2, 2024; June 4, 2024; October 2, 2024. | |
| NIH | NIH Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed) | -- | This encourages innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. | February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024. | |
| NIH | NIH Dissemination and Implementation Research in Health | -- | Supports studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. • R01 Clinical Trial Optional • R03 Clinical Trial Not Allowed • R21 Clinical Trial Optional | R01 Clinical Trial Optional: February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024; October 5, 2024; February 5, 2025. R03 Clinical Trial Not Allowed: February 16, 2023; June 16, 2023; October 16, 2023; February 16, 2024; June 16, 2024; February 16, 2025; June 16, 2025. R21 Clinical Trial Optional: February 16, 2023; June 16, 2023; October 16, 2023; February 16, 2024; June 16, 2024; February 16, 2025; June 16, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Computational and Statistical Methods to Enhance Discovery from Health Data | -- | The National Library of Medicine (NLM) invites research grant applications that propose innovative state-of-the-art methods and generalizable approaches to address problems with large health data sets or analytic tools, whether the data are obtained from electronic health records, public health data sets, biomedical imaging, omics repositories, literature, and social media data, or other biomedical or social/behavioral data sets. Applications in response to this NOSI are expected to help address AI ethical issues and mitigate algorithm bias caused by data problems. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH National Library of Medicine (NLM) Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional) | -- | This focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects. | February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024; October 5, 2024; February 5, 2025; June 5, 2025; October 5, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03) | -- | National Institute on Drug Abuse (NIDA) seeks research on rigorous hypothesis-driven and theory-based study designs and data analytic methods that will support a new generation of patient centered addiction health services research. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. | |
| NIH | NIH Notice of Special Interest (NOSI): Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior | -- | The eXplainable Artificial Intelligence (XAI) framework aims to provide strong predictive value along with a mechanistic understanding of AI solutions by combining machine learning techniques with effective explanatory techniques. This NOSI solicits applications in the area of XAI applied to neuroscientific questions of encoding, decoding, and modulation of neural circuits linked to behavior. This NOSI encourages collaborations between computationally and experimentally focused investigators. This NOSI seeks the development of machine learning algorithms that are able to mechanistically explain how experimental manipulations affect cognitive, affective, or social processing in humans or animals. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through February 5, 2026. | |
| NIH | NIH NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required) | -- | This is for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. They may include studies of drugs and biologics, feasibility or preliminary efficacy studies of devices, and early studies of surgical, behavioral or rehabilitation therapies. | February 8, 2023; June 13, 2023; October 10, 2023; February 8, 2024; June 10, 2024; October 8, 2024; February 10, 2025. | |
| NIH | NIH NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) | -- | This is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. | February 9, 2023; June 9, 2023; October 10, 2023; February 9, 2024. | |
| NIH | NIH Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) | -- | The National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer's, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. | February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024. | |
| NIH | NIH Multi-Site Investigator-Initiated Clinical Trials: Various Opportunities | -- | These support investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which must be relevant to the research mission of the National Heart, Lung, and Blood Institute (NHLBI). Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required) Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. | February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024; February 11, 2025; June 11, 2025. | |
| NIH | NIH Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) | -- | This supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials must be relevant to the research mission of the National Heart, Lung, and Blood Institute (NHLBI). | February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024; February 11, 2025; June 11, 2025. | |
| NIH | NIH Dementia Care and Caregiver Support Intervention Research | -- | • R01 Research Project Grant - Clinical Trial Required: This solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the • NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) and of those providing their care. • R61/R33 - Clinical Trial Required: This will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings. This will support Stage I or Stage III pilot research to test the feasibility of implementing and integrating interventions (R61 phase) that, if successful, can transition to an R33 phase (Stage IV) for implementation of large pragmatic trials. | February 10, 2023; October 10, 2023; February 13, 2024. | |
| NIH | NIH NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | -- | This supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. It does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways, molecular mechanisms, or mechanisms of metastasis), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. | February 13, 2023; June 12, 2023; October 10, 2023; February 13, 2024; June 12, 2024; October 10, 2024; February 13, 2025; June 12, 2025. | |
| NIH | NIH National Institute of Mental Health (NIMH) Clinical Trial Funding Opportunity Announcements (FOAs): Various Opportunities | -- | NIMH solicits clinical trial applications through a series of FOAs that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. • PAR-21-129: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required) • PAR-21-130: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required) • PAR-21-131: Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required) • PAR-21-132: Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required) • PAR-21-134: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required) • PAR-21-135: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required) • PAR-21-136: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required) • PAR-21-137: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required) | February 15, 2023; June 15, 2023; October 17, 2023; February 15, 2024. | |
| NIH | NIH High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) | -- | This supports high priority research at the intersection of HIV and substance use. It is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. | February 15, 2023; August 15, 2023; February 15, 2024. | |
| NIH | NIH - Notice of Special Interest (NOSI): Small Research Grants for Innovations in Healthy Longevity Research | -- | The National Institute on Aging's (NIA) is interested in projects that reflect its mission to support research on aging, the aging process, and diseases and conditions associated with growing older, including Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Applications that reflect NIA's programmatic interests in genetic, biological, clinical, epidemiological, neuroscience, behavioral, social, and economic research on aging as they relate to healthy longevity are encouraged. | This notice applies to due dates on or after February 16, 2023 and subsequent receipt dates through May 8, 2023. | |
| NIH | NIH Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed) | -- | The study must address questions within the mission and research interests of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice. | February 17, 2023; June 19, 2023; October 18, 2023; February 20, 2024; June 18, 2024; October 18, 2024; February 19, 2025. | |
| NIH | NIH Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed) | -- | This invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. | February 17, 2023; August 17, 2023; February 20, 2024; August 19, 2024; February 19, 2025. | |
| NIH | NIH Ethical, Legal and Social Implications (ELSI) Research: Various Opportunities | -- | R01 Clinical Trial Optional: Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders. R21 Clinical Trial Optional: These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information. R03 Clinical Trial Optional: These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data. | February 17, 2023; June 19, 2023. | |
| NIH | NIH Translational Neural Devices (UG3/UH3 - Clinical Trial Optional) | -- | This encourages investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. | February 21, 2023; June 19, 2023; October 18, 2023; February 20, 2024. | |
| NIH | NIH Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) | -- | This supports the phased development of in vivo assays to address translational gaps in treatment development for mental disorders. Support will be provided for assay development efforts that propose quantitative measures to assess alterations in neurophysiology/circuit activity that contribute to or reflect clinically relevant domains of function (e.g., cognitive function, impulsivity, motivation, etc.). It supports assays that measure brain functions that are evolutionarily conserved between a selected animal species and humans. | February 21, 2023; June 21, 2023; October 21, 2023; February 21, 2024; June 21, 2024; October 21, 2024; February 21, 2025; June 20, 2025. | |
| NIH | NIH NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional) | -- | This supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. | February 22, 2023; June 20, 2023; October 17, 2023; February 22, 2024; June 20, 2024; October 17, 2024; February 24, 2025; June 20, 2025; October 17, 2025. | |
| NIH | NIH: Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) | -- | This initiative intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. | February 24, 2023; June 26, 2023; October 25, 2023; February 27, 2024; June 25, 2024; October 25, 2024; February 25, 2025; June 25, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Technology Development for Cancer Control and Population Science Research | -- | This is to encourage grant applications for the development of novel technologies to support the needs of cancer control and population sciences research including healthcare delivery research, surveillance research, behavioral research, cancer epidemiology, and population scale -omics research with the goal of driving innovation in this field. | This notice applies to due dates on or after March 1, 2023 and subsequent receipt dates through December 31, 2024. | |
| NIH | NIH Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | -- | This solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. The emphasis is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. | March 1, 2023; September 1, 2023. | |
| NIH | NIH Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | -- | This invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research. This solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. | March 1, 2023; September 1, 2023. | |
| NIH | NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) | -- | This invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to the National Institute on Aging (NIA)'s research mission. Information about NIA's mission can be found on the NIA website. | March 7, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024; October 5, 2024; February 5, 2025; June 5, 2025; October 5, 2025. | |
| NIH | NIH Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | -- | This encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science. | March 7, 2023; November 5, 2023; March 7, 2024. | |
| NIH | NIH Accelerating the Pace of Drug Abuse Research Using Existing Data | -- | This invites applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. Primary data collection is not allowed for applications. • R21 Clinical Trial Optional • R01 Clinical Trial Optional | March 7, 2023; August 9, 2023; November 15, 2023; March 4, 2024; August 5, 2024; November 15, 2024. | |
| NIH | NIH Research on Current Topics in Alzheimer's Disease and Its Related Dementias | This invites applications proposing research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD). Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this announcement. Applications proposing research on topics beyond those specified in the notices will not be prioritized for funding. • R21 Clinical Trial Optional: For applications that need additional preliminary data with broader dissemination to establish them for more general use in this research field. • R01 Clinical Trial Optional | March 10, 2023; July 10, 2023; November 13, 2023; March 11, 2024; July 9, 2024; November 12, 2024. | ||
| NIH | NIH Notice of Special Interest (NOSI): Advancing Research for Amyotrophic Lateral Sclerosis (ALS) | -- | The National Institute of Neurological Disorders and Stroke (NINDS) encourages applications to advance research activities relevant to strategic priorities for the ALS research community identified in a recent planning effort of NINDS, including Data Harmonization, Curation, and Analysis; Development of Biomarkers and Biomarker Signatures to Optimize Clinical Trials and Clinical Care Decisions; and Therapy Development for ALS. | This notice applies to due dates on or after March 14, 2023, and subsequent receipt dates through June 24, 2024. | |
| NIH | NIH Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed) | -- | This will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/ Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation. | March 15, 2023; March 15, 2024; March 14, 2025 | |
| NIH | NIH Natural History and Biomarker Studies of Rare Neurodegenerative Diseases (U01) Clinical Trials Optional | Up to USD 0,000 total costs for up to 4 years. | This supports efficient natural history studies and/or biomarker studies that fill unmet needs for rare neurodegenerative diseases for children and adults. Through the support of prospective natural history and/or biomarker studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare neurodegenerative disease or multiple rare neurodegenerative diseases with similar pathophysiology, and facilitate rare disease product development. | May 4, 2023. | |
| NIH | NIH International Centers of Excellence for Malaria Research (U19 Clinical Trial Not Allowed) | -- | This solicits applications for the International Centers of Excellence for Malaria Research (ICEMR) Program, a multidisciplinary network of Centers that will conduct research in malaria-endemic sites to 1) improve our understanding of malaria pathogenesis, epidemiology, and transmission; and 2) evaluate, optimize, and inform development of interventions to understand, control, eliminate, and eventually eradicate malaria. This program is intended to support research that is conducted primarily in countries in which malaria is endemic, and must provide for significant involvement of local/regional researchers in study design, development, and execution. | May 4, 2023. | |
| NIH | NIH Patient Activation for Self-Management of Chronic Conditions (R01 Clinical Trial Optional) | -- | This encourages grant applications that address the influence of patient activation on self-management of chronic conditions. | AIDS Applications: May 7, 2023. | |
| NIH | NIH Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration | -- | The specific research objectives of this NOSI are to rapidly expand the knowledge base on acute and long-term neurological and neurocognitive sequelae of COVID-19. NIA encourages investigator-initiated new and resubmission applications for research activity codes (i.e., R21, R01, R03) to address significant questions about the neurological and neurocognitive impacts of COVID-19 infection in aging and the interaction in older adults of COVID-19 with comorbid conditions, including Alzheimer's disease (AD) and AD-related dementias (ADRD). | This notice applies to subsequent receipt dates through May 7, 2023. | |
| NIH | NIH Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services | -- | The National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), and Office of Research on Women’s Health (ORWH) are issuing this NOSI to outline priorities for research in crisis response services. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems, as well as applications that address crisis services for children and under-resourced populations. | This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Heart, Lung, Blood and Sleep Focused Ancillary Studies to Large Ongoing Clinical Studies (Revised) | -- | This seeks to expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within the mission of the National Heart, Lung, and Blood Institute (NHLBI) by leveraging ongoing clinical research studies through ancillary studies. The purpose is to invite research project applications to conduct focused ancillary studies to large ongoing clinical trials (including late-stage T4 implementation clinical trials), observational studies, and registries. | This notice applies to subsequent receipt dates through May 8, 2023. | |
| NIH | NIH Notice of Special Interest (NOSI): Adopting Techniques and Tools Developed from the BRAIN Initiative Toward National Institute of Mental Health (NIMH) Strategic Research Priorities | -- | NIMH is encouraging the submission of applications proposing to use the following types of tools/technologies developed in the BRAIN Initiative: • Technologies that enable causal in vivo behavioral neuroscience experimental designs to probe functions of neural circuits implicated in the above-mentioned behavioral domains • Technologies that analyze and manipulate complex circuits with a goal to provide comprehensive circuit diagrams • Technologies that monitor neural activity and in vivo behaviors • Interventional tools • Technologies that allow examination of developmental time course and/or sex differences in mental health-relevant circuit function • Computational modeling approaches and data analysis | This notice applies to receipt dates through May 8, 2023. | |
| NIH | NIH Notice of Special Interest (NOSI) – Research on Rehabilitation Needs Associated with the COVID-19 Pandemic | -- | The purpose of this NOSI is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation: • Encourage research to address the rehabilitation needs of survivors of COVID-19 • Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions • Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities | This notice applies to receipt dates through May 8, 2023. | |
| NIH | NIH National Eye Institute (NEI) Collaborative Clinical Vision Project: Various Opportunities | -- | These support to support investigator-initiated large-scale clinical trials, human gene-transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. The proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. • Chair's Grant (UG1-Clinical Trial Required): This encourages applications for the Chair's grant, which includes the scientific rationale, study aims and significance of the research project. • Coordinating Center Grant (UG1 Clinical Trial Required):This encourages applications for the Coordinating Center grant, which provides details of the Coordinating Center's responsibilities and operations. • Resource Center Grant (UG1- Clinical Trial Required): This encourages applications for the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial or other complex or high-risk clinical trial. | Standard dates apply until May 8, 2023. | |
| NIH | NIH Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities | -- | The purpose is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science (SMSS) to understand and address minority health and health disparities. | Standard dates apply until May 8, 2023. | |
| NIH | NIH Notices of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems | -- | The Office of Disease Prevention and participating Institutes, Centers and Offices (ICOs) are issuing this Notice to communicate our interest in research examining how electronic nicotine delivery systems (ENDS) affect normal and disease states relevant to human cells, tissues, organs, and behaviors. Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered. | • Basic Mechanisms of Health Effects:This Notice applies to subsequent receipt dates through May 9, 2023. • Population, Clinical and Applied Prevention Mechanisms of Health Effects:This Notice applies to subsequent receipt dates through May 9, 2024. | |
| NIH | NIH Innovations to Optimize HIV Prevention and Care Continuum Outcomes | The National Institute of Mental Health (NIMH) invites applications that propose to advance innovative research to optimize HIV prevention, treatment, and care. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, large-scale intervention efficacy or effectiveness trials, implementation science studies, or data science approaches to optimize HIV prevention, treatment, and care. • R01 Clinical Trial Optional: For applications with preliminary data or those including longitudinal analysis, advanced modeling, large-scale clinical trials or implementation science studies. • R21 Clinical Trial Optional: For exploratory, novel studies that break new ground, extend previous discoveries in new directions or result in novel techniques or models. • R34 Clinical Trial Optional: For applications proposing the initial development and pilot testing of a clinical trial or formative implementation research. | May 9, 2023; September 8, 2023; January 9, 2024; May 9, 2024; September 10, 2024; January 9, 2025; May 9, 2025; September 9, 2025; January 9, 2026. | ||
| NIH | NIH Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) | -- | Invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of the participating IC [National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Aging (NIA)]. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. | May 15, 2023; September 13, 2023; January 16, 2024; May 13, 2024; September 13, 2024; January 13, 2025; May 13, 2025; September 15, 2025; January 13, 2026 | |
| NIH | NIH Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) | -- | This solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The goal of the program is to support technological innovations that deliver new capabilities, which can realize meaningful solutions within 5-10 years. Projects may span the development in the research settings, validation, translation into clinical settings as needed, and incorporation of these solutions as endpoints into research protocols to enhance our understanding of life science processes or the practice of medicine to benefit patients. | May 26, 2023; September 26, 2023; May 24, 2024; September 26, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy | -- | This NOSI will support research that focuses on the basic mechanisms of COVID-19 associated thrombosis ranging from vascular endothelial cell injury, the host immune responses, to the coagulation and fibrinolysis systems. Identifying risk factors, or co-morbidities that predispose patients to COVID-19-Associated Coagulopathy (CAC) are also of interest | This notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through July 5, 2025. | |
| NIH | NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required) | -- | This encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. | June 6, 2023; October 6, 2023; February 6, 2024; June 10, 2024; October 8, 2024; February 7, 2025; June 6, 2025; October 7, 2025; February 6, 2026. | |
| NIH | NIH Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional) | -- | This supports applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical). | June 7, 2023; October 9, 2023; June 7, 2024; October 8, 2024 | |
| NIH | NIH HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed) | -- | This supports interdisciplinary team-based research projects to develop assays, conduct screening and early optimization work followed by pharmacokinetic, pharmacodynamic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development. Discovery and validation of pharmacodynamic markers as well as development and validation of animal models or outcome measures are also responsive. | June 9, 2023; October 10, 2023. | |
| NIH | NIH HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed) | -- | The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards. The limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. | June 9, 2023; and October 10, 2023. | |
| NIH | NIH Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery: Various Opportunities | -- | This invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. • PAR-21-349 (R01 Basic Experimental Studies with Humans Required): Types of projects include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolation. Applications should not propose a goal of clinical outcomes or products. • PAR-21-350 (R01 Clinical Trials Not Allowed): For applications that propose studies including model animal research or observational studies involving humans. Both animal model and human subjects research projects are welcome; however, clinical trials are not allowed. • PAR-21-352 (R01 Clinical Trial Required): Types of projects include mechanistic studies that are classified as clinical trials. Types of studies include clinical trials that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. | June 21, 2023; June 21, 2024. | |
| NIH | NIH BRAIN Initiative: Targeted BRAIN Circuits Projects | -- | • R34 Clinical Trials Not Allowed: For applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying hat, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01 • R01 Clinical Trial Not Allowed: For research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. | R34 Clinical Trials Not Allowed: June 30, 2023; October 4, 2023; June 28, 2024; October 2, 2024. R01 Clinical Trial Not Allowed: June 30, 2023; October 4, 2023; June 28, 2024; October 2, 2024. | |
| NIH | NIH New Models of Integrated HIV/AIDS, Addiction, and Primary Care Service | -- | This supports the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services. • PAR-20-273 (R01 Clinical Trial Required): This seeks applications that will test comprehensive service delivery models. Applicants needing to develop, refine, and/or test key components of such a model are encouraged to apply to the companion R34. • PAR-20-274 (R34 - Clinical Trial Optional): The R34 grant mechanism is intended to encourage planning research by providing support for the initial development of a clinical trial or research project. | August 11, 2023. | |
| NIH | NIH BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed) | -- | This seeks the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. Proposed projects could develop tools to integrate existing theories or formulate new theories; conceptual frameworks to organize or fuse data to infer general principles of brain function; multiscale/multiphysics models to generate new testable hypotheses to design/drive future experiments; new analytical methods to substantiate falsifiable hypotheses about brain function. | September 12, 2023; September 12, 2024. | |
| NIH | NIH Using Secondary Data Analysis to Determine Whether Preventive Interventions Implemented Earlier in Life Reduce Suicide Risk (U01 Clinical Trial Not Allowed) | Up to USD ,000,000 for up to 4 years. | This is to encourage research that will integrate and harmonize existing large prevention trial data sets. The data sets should consist of well-characterized participant-level data for interventions implemented earlier in life to examine whether they reduce risk for later suicide, including suicidal thoughts and behaviors — fatal and nonfatal (STB), and related external injuries (e.g., nonfatal SUD/OUD/accidents, and all-cause mortality (e.g., National Death Index)). | Up to USD ,000,000 for up to 4 years. | |
| NIH | NIH BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development (UG3/UH3 Clinical Trial Not Allowed) | -- | This is for team-centric development and validation of innovative non-invasive imaging technologies that could have a transformative impact on the study of brain function/connectivity. Applications are expected to turn a novel concept into a functional prototype using this phased grant mechanism. | October 13, 2023. | |
| NIH | NIH Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed) | -- | This supports hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI). | December 7, 2023; December 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research | -- | This is to encourage grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, clinical, and intervention research. The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI algorithms. | This Notice applies to due dates until March 9, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments | -- | The purpose of this Notice is to inform potential applicants of the interest of the National Cancer Institute (NCI) in supporting implementation research related to cancer prevention and control in low- and middle-income countries. NCI encourages applications that pursue innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines in low-resource settings. | This notice applies to subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Dissemination and Implementation Research to Advance Mental, Emotional, and Behavioral Health Preventive Interventions in School Settings | -- | The purpose is to stimulate dissemination and implementation research to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based preventive interventions to support children's mental, emotional, and behavioral (MEB) health in school settings. | This Notice applies to due dates until June 5, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM) Populations | -- | This encourages research that describes the biological, clinical, behavioral, and social processes that affect the health and development of SGM populations and individuals and their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that will enhance health and development of these populations. | This notice applies to subsequent receipt dates through August 1, 2025. | |
| NIH | NIH BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed) | -- | This aims to develop standards that describe experimental protocols conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will encompass the data collection efforts of those groups. The developed standard is expected to be broadly disseminated for use and widely available. | June 14, 2023; June 14, 2024. | |
| NIH | NIH Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia (R01 Basic Experimental Studies with Humans Required) | -- | This encourages research to develop task-based behavioral measures that are shown to engage brain systems relevant to anhedonia using neuroimaging or other brain measures with similar spatial resolution. The goal is to identify behavioral tasks that can be used as quantitative tools in future studies of the functional constructs associated with anhedonia and in treatment development. This is for basic science experimental studies involving human participants that fall within the NIH definition of a clinical trial and also meet the definition of basic research. | Standard dates apply until September 8, 2023. | |
| NIH | Occupational Safety and Health Research (R01) | -- | The purpose is (1) to develop an understanding of the risks and conditions associated with occupational diseases and injuries, (2) to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and (3) to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries. | Standard dates apply until November 18, 2023. | |
| NIH | NIH Notice of Special Interest (NOSI): Developing Digital Therapeutics for Substance Use Disorders | -- | The National Institute on Drug Abuse (NIDA) seeks applications that stimulate research to support the development and testing of Digital Therapeutics (DTx) to treat Opioid Use Disorders (OUD) or Polysubstance Use Disorders (PUD) as stand-alone interventions or integrated with FDA-approved medication treatments. | This notice applies to subsequent receipt dates through December 7, 2023. | |
| NIH | NIH Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional) | -- | This seeks to broaden and strengthen patient-centric translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH). | • PAR-21-342: Pre-application (recommended, not required). Deadlines: December 13, 2022; December 13, 2023. • PAR-21-343: Application. Deadlines: April 18, 2022; April 18, 2023; April 18, 2024. | |
| NIH | NIH Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer | -- | This intends to focus on basic mechanistic and translational studies to investigate HIV and cancer in underrepresented groups. Underrepresented groups include racial, ethnic, and gender minorities, including underserved minorities living in geographical areas that have high numbers of new HIV infections (e.g., Southern and some urban areas in the United States, international sites that have higher rates of underlying HIV infection). Mechanistic and/or translational studies that examine how different comorbidities, associated behaviors, and other disorders (e.g., diabetes, smoking, injecting drug users, obesity, etc.), contribute to the initiation, progression and disease sequelae in underserved populations may be proposed. • R21 Clinical Trial Not Allowed • R01 Clinical Trial Not Allowed | December 15, 2023. | |
| NIH | NIH BRAIN Initiative: Brain-Behavior Quantification and Synchronization – Transformative and Integrative Models of Behavior at the Organismal Level (R34 Clinical Trial Not Allowed) | -- | This supports the development and validation of next-generation tools, methods, and analytic approaches to precisely quantify behaviors and combine them with simultaneous recordings of brain activity in humans. Tools used for measuring and analyzing behavior should be multi-modal, with the appropriate accuracy, specificity, temporal resolution, and flexibility necessary for integration with existing tools used to measure and modulate the brain circuits that give rise to those behaviors. | February 17, 2023; February 15, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes | -- | This supports applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. These include, but are not limited to: • Investigation of aging trajectories associated with specific cancer treatments and identification of cancer survivors at risk for an “accelerated aging” phenotype; • Examination of the effects of specific cancer treatments on aging biology that may alter aging trajectories or aging outcomes; • Development and/or validation of tools, technologies, measures, or techniques for the identification of late-emerging effects and aging phenotypes among cancer survivors; • Use of old and young animal models to determine the effects of established and newer cancer therapies on aging endpoints; • Development and/or testing of interventions designed to prevent, mitigate or reverse the adverse aging-related effects of cancer and cancer treatments; and • Development and/or testing of interventions focused on models and processes of care delivery to intervene at the intersection of cancer treatment and aging. | This notice applies to receipt dates through January 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers | -- | This supports the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This encourages applications proposing multi-institutional collaborative AI development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data. | This notice applies to subsequent receipt dates through January 8, 2024. | |
| NIH | NIH Priority HIV/AIDS Research within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 Clinical Trial Optional) | -- | This seeks to stimulate HIV/AIDS research within the mission of the NIDDK that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. | Standard AIDS dates apply until January 8, 2024. | |
| NIH | NIH Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R21 Clinical Trial Not Allowed) | -- | This is for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Potential topics could address multiple overarching priorities. | Standard AIDS dates apply until January 8, 2024. | |
| NIH | NIH Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | -- | This supports investigator-initiated clinical that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. | Standard dates apply until January 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders | -- | National Heart, Lung, and Blood Institute (NHLBI) seeks to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions. | This notice applies to receipt dates through January 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition | - | This encourages applications in high-priority research areas related to pediatric health care transition for youth with chronic physical/medical conditions or intellectual/developmental disabilities. Research applications that will advance our understanding of promising practices designed to facilitate successful health care transitions (HCT) from pediatric to adult care settings as well as barriers and facilitators to such transition are encouraged. | This notice applies to subsequent receipt dates through January 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Telehealth in Cancer Care | -- | This supports investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged. | This notice applies to subsequent receipt dates through March 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research | -- | This encourages grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, clinical, and intervention research. The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI algorithms. | This notice applies to subsequent receipt dates through March 9, 2024. | |
| NIH | NIH Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes | -- | National Institute of Mental Health (NIMH) seeks applications to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus and intensity/burden. PAR-21-211 (R34 Clinical Trial Required): This supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. PAR-21-210 (R01 Clinical Trial Required): This supports fully-powered, definitive effectiveness studies focused on post-acute phase interventions | Standard dates apply until March 17, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies | -- | National Institute of Allergy and Infectious Diseases (NIAID) is interested in the development and optimization of next generation methodologies for HIV-1 drug resistance (DR) mutation detection and reporting. Strategies applicable to low and middle income countries as defined by the World Bank are especially encouraged. National Institute on Drug Abuse (NIDA) is interested in the following areas: Feasibility of self-administered, cost effective, and potential for mail-in testing and follow up through mobile technologies targeting substance-using populations living with HIV; Development of technologies that allow sensitive and rapid read out of drug resistance; Plans for post-administering surveys to assess rates of access, acceptability (stigma and ethical concerns), accuracy, and treatment outcomes; Technologies that are easily adaptable for implementation in homeless shelters, community clinics, criminal justice, and emergency department settings. | This notice applies to subsequent receipt dates through May 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV | -- | This is to promote and support innovative methods in Big Data Science (BDS) to identify unappreciated biomedical, behavioral, social patterns and other social determinants that shed light on HIV acquisition, transmission, the development of comorbidities, and long-term viral control as in the HIV treatment continuum. BDS approaches can bring together data to evaluate the complex interplay between individual, contextual, and structural factors influencing the epidemiology of risk and care. This NOSI will support the establishment of BDS standards, bioinformatics data tools, machine-learning algorithms, mathematical modeling, advanced epidemiology and statistical analytic methods, and consideration and application of privacy and ethical issues in the use of public and personal data in the context of HIV research. | This notice applies to subsequent receipt dates through May 7, 2024. | |
| NIH | NIH Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) | -- | This supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. | Standard dates apply until May 8, 2024. | |
| NIH | NIH NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed) | -- | This supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. | Standard dates apply until May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI) regarding the Use of Human Connectome Data for Secondary Analysis | -- | This encourages secondary analyses of data from the Human Connectome Project (HCP), including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease. | This notice applies to receipt dates through May 8, 2024. | |
| NIH | NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): Various Opportunities | Up to USD ,000 per year for up to 2 years. | PA-21-231 (R03 Basic Experimental Studies with Humans Required): This is for basic science experimental studies involving humans. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. PA-21-221 (R03 Clinical Trial Required): This supports clinical trials that fall within the NICHD mission. | Standard dates apply until May 8, 2024. | |
| NIH | NIH Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment | -- | The purpose is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. Each partnership should include at least one academic and one industrial organization. • PAR-21-166: R01 - Clinical Trial Not Allowed • PAR-21-206: R01 - Clinical Trial Optional | Standard dates apply until May 8, 2024. | |
| NIH | NIH Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity: Various Opportunities | -- | The purpose of these Funding Opportunity Announcements (FOAs) is to lay the groundwork for developing interventions at the network/circuit level that might be used as potential treatments for cognitive, affective, or social deficits in psychiatric disorders. These FOAs support projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. PAR-21-175 (R01 Clinical Trial Optional) PAR-21-176 (R21 Clinical Trial Optional) | Standard dates apply until May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI) HIV/AIDS in the Era of COVID-19: When Pandemics Collide | -- | This is to communicate special interest in epidemiology investigations to quantify the impact of the COVID-19 pandemic on HIV prevention, incidence, transmission, and outcomes. This NOSI encourages research on the impact and strategies needed to adapt the HIV/AIDS response through agile and innovative support of prevention and care and the maintenance of sustained HIV viral suppression during the COVID-19 pandemic. | This notice applies to due dates on or after September 7, 2021 and subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities | -- | This NOSI encourages applications that address dimensions of access, acceptance and uptake of CDC-recommended vaccines among infants, children, adolescents, pregnant and lactating women, and persons with disabilities, especially among populations who are underserved or experience health disparities. | This notice applies to due dates on or after September 8, 2021 and subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure | -- | To address knowledge gaps that will improve HIV outcomes, this calls for research that will improve scientific understanding of health communication as it relates to ongoing HIV prevention, diagnosis, treatment and cure efforts, as well as research on communication, dissemination and implementation factors that are required for successful public understanding, acceptance and uptake of HIV-related interventions. | This notice applies to due dates on or after April 8, 2021 and subsequent receipt dates through May 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI) - Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities | -- | The purpose is to provide an avenue for researchers to pursue funding to conduct research addressing emerging and existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities. Please see the NOSI for the areas of interest in these populations. | This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through June 6, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health | -- | This calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. | This notice applies to subsequent receipt dates through June 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI) | -- | This NOSI seeks to support investigation into the factors and molecular mechanisms that address the heterogeneity dictated by the host resilience. Research on general host responses to injurious challenges and their effects on lung function as well as mechanisms that impact susceptibility to ARDS is not considered to be responsive to this announcement. | This notice applies to receipt dates through July 5, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning | -- | This encourages grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. National Institute on Drug Abuse (NIDA) is interested in applications that make use of existing data, such as epidemiologic cohorts, clinic cohorts and longitudinal follow-up studies of interventions, as well as other publicly available sources of data including data warehouses and commercial data sources. Substance use should be a key component of any research supported by this NOSI. | This notice applies to subsequent receipt dates through September 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19 | -- | National Institute on Drug Abuse (NIDA) is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19. | This notice applies to due dates through September 7, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection | -- | This NOSI encourages research to understand: • The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection. • The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana. • The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer. | This notice applies to due dates through September 8, 2024. | |
| NIH | NIH Basic Research in Cancer Health Disparities | -- | This encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. • - R01 Clinical Trial Not Allowed: These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities. • - R21 Clinical Trial Not Allowed: This provides support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities. • - R03 Clinical Trial Not Allowed These small research grants will support projects on cancer health disparities that can be carried out in a short period of time with limited resources. | Standard dates apply until September 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to improve use of Evidence-Based Practices for heart, lung, blood, and sleep (HLBS) conditions | -- | National Heart, Lung, and Blood Institute (NHLBI) encourages applications that recognize the importance of cultural context, patterns of behavior change, and motivators for change across decision-making levels, including individuals (e.g., patients, parents, clinicians, others), groups, healthcare systems and/or communities. | This notice applies to subsequent receipt dates through September 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research | -- | The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the US. Applications examining all areas of National Institute on Drug Abuse (NIDA)-supported research addressing the causes, consequences, treatment, and prevention of drug use, misuse, and addiction are encouraged. Projects should be conducted through newly formed or well-established partnerships between an investigator in a US-based institution and a scientist working in another country. | This notice applies to subsequent receipt dates through September 8, 2024. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment | -- | The purpose is to stimulate research that identifies effective strategies for improving interprofessional teamwork and addresses care coordination challenges within care settings and between care settings (e.g., between tertiary care and community settings) or during care transitions (e.g., from inpatient to outpatient care). Research in this area should advance actionable knowledge about how to design and carry out effective, efficient interprofessional team-based cancer care that improves quality and patient outcomes. Research that is focused on the needs of racial/ethnic minority, medically underserved, or low-income populations and/or those receiving care in community settings (including, but not limited to, community-based cancer centers or clinics) is not required, but strongly encouraged. | This notice applies to subsequent receipt dates through October 9, 2024. | |
| NIH | NIH Clinical Trial Readiness for Functional Neurological Disorders (FNDs) (U01 Clinical Trial Optional) | -- | This invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this funding opportunity announcement include the validation of biomarkers, endpoints and clinical outcome assessments that are fit-for-purpose and have a defined context of use for clinical trials | Standard dates apply until November 6, 2024. | |
| NIH | NIH Neuromodulation/Neurostimulation Device Development for Mental Health Applications | -- | This encourages applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared. • R01 Clinical Trial Not Allowed: For applicants who seek to propose a larger project. Applicants who seek to establish proof-of-concept should respond to the companion R21. • R21 Clinical Trial Not Allowed: This uses the R21 grant mechanism, encouraging shorter, higher-risk applications. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope. | Standard dates apply until January 8, 2025. | |
| NIH | NIH - Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest | -- | This aims to study the effect of emerging and evolving public health crises and/or policy changes on the health, development, and well-being of populations of interest to the NICHD: neonates, infants, children, adolescents, and young adults, pregnant and post-partum and nursing people, individuals of reproductive age, and individuals with intellectual, developmental, or physical disabilities, as well as the families of these individuals. | This notice applies to subsequent receipt dates through January 8, 2025. | |
| NIH | NIH Drug Discovery for Nervous System Disorders | -- | NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents. • R01 Clinical Trials Not Allowed: Applicants with preliminary data may wish to apply using the R01 mechanism. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism. • R21 Clinical Trials Not Allowed: This will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). | Standard dates apply until January 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research | -- | National Institute of Mental Health (NIMH) is issuing this NOSI to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress, disruptions, and loss of lives in the pandemic. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH. Research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting and worsening health disparities. | This Notice applies to subsequent receipt dates through January 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Public Health Research on Cannabis | -- | The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health. | This notice applies to subsequent receipt dates through May 5, 2025. | |
| NIH | NIH Laboratories to Optimize Digital Health (R01 Clinical Trial Required) | -- | This is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations. | Standard dates apply until May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Research to Prevent Drug Use, Misuse and Addiction | -- | The National Institute on Drug Abuse (NIDA) is issuing this Notice to encourage grant applications in research on the prevention of risky drug use behaviors and addiction. The research may include studies to: 1) develop and test strategies to prevent the initiation of substance use, progression to substance use disorders, or to prevent substance use-related conditions such as HIV; 2) develop and test processes or strategies to implement, scale, and sustain evidence-based prevention in community, practice, and service systems;and,3) develop methods to conduct prevention science. Primary outcomes of interest for submitted applications include preventing initiation of substance use, misuse, and progression to disorder, as well as prevention of HIV infection. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening | -- | This is to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. It encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. | This NOSI applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan | -- | This encourages highly innovative translational research focused on the delivery of multilevel interventions to improve uptake of evidence-based screening services that promote health equity and that are recommended by expert committees. At minimum, the proposed studies must: Include screening as a primary outcome; Inform the development of OR test an intervention or strategy that acts on at least two socioecological levels; and, Include OR test an intervention or strategy that demonstrates high potential for scalability and sustainability. | This notice applies to subsequent receipt dates through May 8, 2025. | |
| NIH | NIH NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed) | -- | The purpose is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This may be used to develop new statistical methodologies or test hypotheses using existing data, but must not be used to support the collection of new data. | Standard dates apply until May 8, 2025. | |
| NIH | NIH NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed) | -- | This supports applicants in their planning efforts to conduct collaborative large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. The grant may be used to support the development of a Manual of Procedures (MOP), as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. | Standard dates apply until May 8, 2025. | |
| NIH | NIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) | -- | This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address National Institute of Mental Health (NIMH) strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. | Standard due dates apply until May 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): BRAIN Initiative: Developing Data Archive, Informatics Tools and Data Standards for Brain Behavior Quantification and Synchronization (BBQS) | -- | The purpose of is to encourage new applications for developing informatics infrastructure for BBQS) research program of the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative. Specifically, the NOSI supports a) creation of data archive(s) to store and manage BBQS-relevant data; b) development of computational tools or software for analyzing, visualizing and integrating BBQS-related data, and for predicting and modeling the complex dynamics of the brain-behavior system; and c) establishment of data standards or ontologies that support the BBQS-related studies. | Submission of an application in response to this NOSI should use one of the following: BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed): June 9, 2023; October 13, 2023; June 7, 2024. BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed): June 14, 2023; June 14, 2024. BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional): July 14, 2023. | |
| NIH | NIH Informatics Technologies for Cancer Research and Management | -- | This invites applications for the development of innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. • Development of Innovative Informatics Methods and Algorithms (R21 Clinical Trial Optional) This supports the development of novel informatics capabilities that involve a high degree of innovation that have the potential to accelerate or enhance research. • Early-Stage Development (U01 Clinical Trial Optional) For initial tool development or the significant modification of existing tools for new applications. • Advanced Development (U24 Clinical Trial Optional) For emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. • Sustained Support (U24 Clinical Trial Optional) This focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. | June 13, 2023; November 17, 2023. | |
| NIH | NIH HEAL Initiative Notice of Special Interest (NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery | -- | This is to encourage the development, validation, and replication of animal models that recapitulate the phenotypic and physiologic characteristics of a defined pain type/indication and/or disease-associated pain condition and endpoints or outcome measures that can be used therein. | This notice applies to due dates on or after October 18, 2022 and subsequent receipt dates through June 25, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations | -- | This seeks applications for diagnostics and disease management tools that have the power to deliver breakthroughs to enable prevention and treatment of heart, lung, blood and sleep diseases in underserved communities. Investigators will be required to engage community partners at the onset and throughout their research project. | This notice applies to due dates on or after February 5, 2022 and subsequent receipt dates through July 6, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01) | -- | This promotes research characterizing the pathobiological processes and mechanisms that drive the onset and progression of lung diseases at a molecular/cellular level, providing a systems-level understanding by studying experimental systems with cellular heterogeneity and 3-D architecture. Projects will utilize ex vivo preparations (e.g., thin human lung slices) or 3-D multi-cellular in vitro systems (e.g., organoids) of human lung cells and will employ state-of-art multi-omics measures (e.g., spatial or single cell/nucleus omics). | This notice applies to due dates on or after September 25, 2022 and subsequent receipt dates through September 7, 2025. | |
| NIH | NIH: Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities | -- | The purpose of this NOSI is to solicit projects on preventive interventions that address cardiometabolic risk factors in populations that experience health disparities. | This notice applies to due dates on or after October 5, 2022 and subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Epidemiology of Drug Abuse | -- | This encourages the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Of interest are applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease outcomes. | This Notice applies to applies to due dates on or after June 5, 2022 and subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Bioengineering Research Grants (BRG) | -- | This is to encourage collaborations- between life science and physical science- that: 1) apply a multidisciplinary bioengineering approach to solve biomedical problems; and 2) develop, integrate, optimize, validate, translate or accelerate adoption of promising tools, methods and techniques: a) that fulfill an unmet need and address specific research or clinical problem in basic, translational, and/or clinical science and practice, b) capable of enhancing our understanding of health and disease, and/or c) improve practice of medicine. • R01 Clinical Trial Not Allowed: This is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science. • R01 Clinical Trial Optional: This will support clinical trials that test functionality or validate performance in the chosen setting. | Standard due dates apply until September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance Use Prevention and Treatment | -- | This supports research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment, 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records). | This notice applies to subsequent receipt dates through September 8, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Development and Implementation of Clinical Informatics Tools to Enhance Patients’ Use of Genomic Information | -- | This encourages applications to develop and implement patient-facing genomic-based clinical informatics tools that facilitate or enhance patient-provider electronic communication, patient tracking and registry functions, patient self-management and support, provider electronic prescribing, test tracking, referral tracking, and health care decision-making. | This notice applies to subsequent receipt dates through September 24, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Research on Addressing Violence to Improve Health Outcomes | -- | This encourages novel intervention research aimed at developing, refining, adapting, and testing interventions focused on preventing violence or addressing acute and chronic effects of violence on physical and behavioral health. Effectiveness, implementation, and hybrid effectiveness-implementation designs are encouraged, as appropriate to the research questions proposed. | This notice applies to subsequent receipt dates through October 5, 2025. | |
| NIH | NIH Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood | -- | This supports support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitionary phases, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years), and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitionary phases. | This notice applies to subsequent receipt dates through June 5, 2026. | |
| NIH | NIH Parent Announcements | -- | • - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) • - NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) • - NIH Research Project Grant (Parent R01 Clinical Trial Required) • - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) • - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) • - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) • - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) | Standard dates apply unless otherwise stated. | |
